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ABSTRACT 
Although melanoma is largely curable when detected in its earliest stages, it can 
metastasise to other tissues, drastically reducing survival rates. The most recent 
therapies used to treat metastatic melanoma are effective long-term in only 11 to 33% of 
patients. Our ability to monitor treatment failure is limited. New prognostic markers are 
urgently required to allow monitoring of treatment response and disease progression. 
Circulating tumour cells (CTCs) are released into the bloodstream by the tumours within 
a patient, this being a key step in melanoma spread. Since CTCs can be detected in the 
blood of metastatic melanoma patients, these cells can be used as a “liquid biopsy”, 
providing critical insight into each person’s melanoma biology. 
Melanoma CTCs have been described as very heterogeneous, hindering their isolation via 
commonly used CTC capturing methods. To address this, microfluidic devices have been 
developed to isolate viable CTCs from blood, independently of their marker expression. 
This study aimed to determine the effectiveness of two different microfluidic devices 
(Slanted and A5) in recovering melanoma cell lines, and their potential use in the isolation 
of CTCs from the blood of metastatic melanoma patients. It also aimed to study additional 
cancer or melanoma specific markers to be used in immunostaining protocols for 
detection of CTCs after microfluidic enrichment. 
The optimal isolation procedure was identified as two rounds of enrichment with the 
Slanted spiral device, after which we obtained a 3-log depletion of white blood cells and 
a recovery of over 60% when cells from two melanoma cell lines were spiked into blood 
samples from healthy volunteers. In addition, we optimised the detection of CTCs using 
four melanoma markers (gp100, Melan-A, s100 and MCSP) combined in a multimarker 
immunocytochemistry staining protocol. The optimised enrichment and detection 
procedures were validated in a cohort of ten metastatic melanoma patients. Results 
showed that 40% of the patients had one or more CTCs in their blood (1-4 CTCs/8 mL of 
blood). 
Furthermore, three additional markers (Vimentin, RANK, and ABCB5) were trialled so as 
to increase detection of highly heterogeneous melanoma CTCs in samples that have been 
processed through the Slanted microfluidic device. 
 
ii 
The improved enrichment and detection of CTCs in the blood of melanoma patients using 
the methods developed as part of this study will facilitate the molecular, genomic and 
functional characterisation of melanoma CTCs. This will ultimately improve our 
understanding of the biology of melanoma CTCs and their role in metastatic spread and 
treatment response. 
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1 1. INTRODUCTION 
1. INTRODUCTION 
Melanoma is an aggressive cutaneous cancer responsible for the majority of skin cancer-
related deaths and its incidence is increasing worldwide1. Generally, patients are 
considered cured after complete surgical resection of the primary tumour. Nevertheless, 
around 20% of patients will develop metastatic disease, which is extremely difficult to 
treat2. 
The use of targeted therapies and immunotherapies has improved the survival of these 
patients, but the prognosis is still poor due to the development of drug resistance to 
targeted therapies and low response rates to immunotherapies. Moreover, adverse side-
effects of current immunotherapies restrict treatment efficacy in some cases3. Therefore, 
new biomarkers are urgently needed to allow personalised monitoring of the disease, 
with the aim to determine treatment response and recurrence at earlier stages. This will 
allow optimal selection of therapy that improves survival rates in patients. 
Circulating tumour cells (CTCs) appear in the peripheral blood from primary or 
metastatic solid tumours as the first step in tumour metastasis. Cancer cells enter the 
bloodstream and travel to distant organs where they may initiate development of a new 
tumour. 
During the last decade, the quantification of CTCs has been described in the literature, as 
a prognostic marker in various tumours such as breast, prostate, colorectal cancer, and 
melanoma4-9. The high heterogeneity of the tumour and the very low concentration of 
CTCs in peripheral blood (1-10 cells per 10 mL), has made the isolation and quantification 
of CTCs a difficult challenge10. The most widely used methods of enrichment rely on 
antibody capture of CTCs. More recently, physical properties of the CTCs have been used 
to improve the isolation, and currently innovative strategies are being developed with 
the aim of improving the capture and detection of these rare cells. 
Microfluidic devices can integrate biological processes into microstructures that handle 
nano- and pico-litre volumes. This technology is becoming popular because of its ability 
to isolate label-free and viable intact CTCs based on their physical properties, such as cell 
size. In addition to this, these devices have several advantages in the isolation of CTCs, 
which make them promising platforms for implementation in clinical settings. The main 
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advantages include low cost, and high-throughput enrichment of CTCs from other cells. 
Successful isolation of CTCs from lung and breast cancer patients by physical size, using 
a microfluidic device, was reported by Warkiani et al.11, 12. The detection of CTCs in the 
blood of these patients at different therapy stages has been shown to be a potential 
prognostic marker of treatment efficacy and patient survival. 
In this study, microfluidic devices11, 12 have been used, for the first time, to enumerate 
CTCs from melanoma patients. Although there are still challenges to be resolved, the 
improvement of CTC isolation and detection procedures will ultimately assist in the 
understanding of CTC biology, the metastatic process, development of a personalised 
guide to treatment efficacy and early prediction of treatment resistance. 
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2. LITERATURE REVIEW 
2.1 Cutaneous Melanoma 
The skin, which is the largest organ in the body, protects us from UV light, injuries and 
infections, among other important functions13. The main layers of the skin are the inner 
dermal layer and the outer epidermal layer. The dermis contains three different types of 
skin cells: squamous cells, basal cells, and melanocytes. Melanocytes are located in the 
basal layer of the epidermis and are responsible for melanin pigment production (Figure 
1). 
 
Figure 1. Representation of normal skin anatomy. Melanocytes are present in the basal layer of 
the epidermis14. 
Cutaneous Melanoma (CM) is a highly aggressive skin tumour originating from the 
neoplastic transformation of melanocytes. Melanoma occurs principally in the skin; 
however, it may also develop in the conjunctiva and uvea of the eye (uveal melanoma), 
on various mucosal membranes with pigmented tissues, such as the gastrointestinal 
tract, oral or genital membranes, meninges, and in internal organs, such as in the central 
nervous system15. 
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2.1.1 Epidemiology 
Cutaneous melanoma is the most serious form of skin cancer, being responsible for 80% 
of skin cancer deaths, even though it represents <5% of all dermatological cancers16. The 
incidence of this aggressive type of cancer is increasing worldwide. New Zealand together 
with Australia are the countries with the highest incidence of melanoma (Figure 2)17. In 
Australia, melanoma was the 4th most commonly diagnosed cancer in 2014 and it is 
estimated that 12,960 new cases of melanoma skin cancer were diagnosed in 201518. 
A male predominance has been observed after the age of 44 years and in the age group of 
20-24 years a female predominance exists in Australia for melanoma over other types of 
cancer19. The location of the tumour varies with age, being on the trunk or extremities 
more commonly in younger ages, but on head and neck locations in advanced ages20. 
 
Figure 2. Incidence rate of melanoma per 100,000 inhabitants in 2012. Australia has the second 
highest incidence worldwide (34.90), behind New Zealand (35.84) followed distantly by 
Switzerland (20.30)21. 
2.1.2 Aetiology 
The first connection between melanoma and the risk factor, UV irradiation, was made by 
Henry Lancaster22. Nowadays, we know that sun exposure or artificial tanning is the 
major known environmental factor associated with cutaneous melanoma, since 
significant mutations have been identified as having direct UVB-induced origin23-26. 
Melanoma has the highest prevalence of C>T transition mutations, and this is driven by 
UV exposure, resulting in the biggest median number of somatic mutations across all 
human cancer types27. 
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Trends in melanoma incidence show that Caucasian race, male gender, and older age are 
characteristics associated with an increased risk of developing melanoma28. Also, fair-
skinned individuals with red or blond hair and many freckles are more likely to suffer 
from the disease29, 30. Having a higher number of moles, also increases the risk of 
developing melanoma31. Other host factors, such as a personal history of melanoma or 
non-melanoma tumours, including other cancers, can increase the risk of developing 
melanoma32, 33. Moreover, a weak immune system or having a disease that weakens the 
immune system, increases the cancer risk, with a higher incidence of cutaneous 
melanoma in patients after organ transplantation due to medical immunosuppression34. 
Genetic factors are also involved in melanoma development. About 10% of all melanomas 
are estimated to be developed due to hereditary susceptibility35. Since William Norris36 
first suggested that melanomas have a hereditary component, the knowledge of 
melanoma genetics has advanced significantly. It is now known that having a family 
history of melanoma increases the risk 1.74 times compared with a negative family 
history of the disease37. Inherited genetic risk factors can be classified by their penetrance 
and prevalence38. 
Rare high penetrance genetic mutations are present in CDKN2A and CDK4 genes and 
prevail in familial melanoma. Both genes are involved in cell-cycle and melanocyte 
senescence. As an example, the CDKN2A gene located on chromosome 9p21.3, encodes 
for two proteins, p14ARF and p16INK, which control cell cycle entry at the G1 checkpoint 
and stabilise p53 expression39. Low penetrance mutations present in the general 
population, also referred to as single nucleotide polymorphisms (SNPs), have been 
detected in genes involved in hair and skin pigmentation, such as MC1R, ASIP, TYR and 
TYRP140-43. Nevertheless, BAP1, POT1, ACD, TERF2IP, and TERT are also considered 
melanoma high penetrance inherited risk genes44. 
There are also non-inherited gene mutations that increase the risk of melanoma. 
Mutations in TP53 tumour suppressor gene mutations caused by UV radiation are present 
in melanoma45. Both sporadic and continuing or chronic UV light exposures are linked to 
the pathogenesis of melanoma and produce extensive although, different mutational 
profiles23, 27. However, more research is needed to better understand the genetics of 
somatic and hereditary melanoma. 
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2.1.3 Diagnosis 
The first step in melanoma diagnosis is the visual characterisation of suspicious lesions. 
A nevus (or mole) is a visual delimited zone of chronic lesion found in the skin or 
mucosa46. Even though a nevus is considered benign, more than 50% of malignant 
melanomas arise from pre-existing nevi47. The principal visual identification of a nevus 
which would suggest a malignant change is established by the “ABCDE criteria”. Visual 
characteristics of a transformed mole comprise: Asymmetry, a Border that is irregular, 
Colour that is uneven, a Diameter longer than 6 millimetres and, a shape, size or colour 
that is Evolving (Figure 3). Other early signs of a malignant change could be itching, 
ulceration or bleeding. By contrast, nodular melanomas do not follow these criteria. They 
have their own "EFG criteria". The lesion is Elevated above the surrounding skin, the 
nodule is Firm to the touch and Growing in size. 
 
Figure 3. Melanomas with characteristic asymmetry, border irregularity, colour variation and 
large diameter48. 
Total body photography is used to assist with the diagnosis of melanoma49. Dermoscopy 
is an important tool that can aid in differentiating melanoma from other types of 
carcinoma or benign lesions50. Some of the diagnostic techniques available for better 
identification of skin cancer include: multispectral imaging, automated diagnosis, 
confocal scanning laser microscopy, ultrasound imaging, magnetic resonance imaging, 
and optical coherence tomography. 
A histological study of a biopsy of a lesion is needed to diagnose malignancy. The 
histopathological criteria of melanoma are based on the characteristics of the lesion such 
as the extent and penetrance of the tumour or the mitotic rate of the cells in the lesion. 
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The discovery of histologic markers that uniquely identify melanocytes in melanoma has 
aided melanoma diagnosis. The most commonly used markers are S-100 calcium binding 
protein51, MART-1/Melan-A52, and HMB-4553, 54. However, new potential 
immunohistochemical markers such as SOX-1055 or MC1R56,57 have been identified to 
assist in the classification of melanocytic tumours. Nowadays, a combination of multiple 
positive histologic markers and histopathological criteria provides the most reliable 
method of diagnosis. 
2.1.4 Staging of melanoma 
To determine the treatment and the prognosis of a patient with melanoma, staging of the 
biopsied material is needed. The American Joint Commission on Cancer (AJCC) updated 
the melanoma classifications in 200958 using the most significant prognostic values as 
shown in Table 1. 
The clinical staging of melanoma is based on the clinical and radiological examination of 
the regional lymph nodes and the micro-staging of the primary excised melanoma. 
Patients are classified into five main groups. In patients with stage 0 (in situ melanoma), 
melanoma is confined to the epidermis and has not invaded deeper skin layers. Patients 
with clinical stages I and II, have no evidence of metastases. Stage III patients have 
evidence of regional and lymph metastases and stage IV melanoma patients have been 
diagnosed with one or more distant metastases59. Pathological staging includes micro-
staging of the primary melanoma and pathological information about the regional lymph 
nodes after partial or complete lymphadenectomy. Both clinical and pathological staging 
are important in melanoma diagnosis for correct decisions. 
The TNM classification is used to stage patients based on the extent of the primary 
tumour (T), the presence or not and the extent of regional lymph node metastases (N), 
and the presence or absence of distant metastases (M)60. The T category is further 
characterised by defining the presence in the primary tumour of ulceration, mitotic rate, 
and tumour thickness as defined by Breslow61. Breslow’s thickness is measured from the 
top of the granular layer of the epidermis or from the base of the ulcer to the deepest 
dermal invasive cell if the surface is ulcerated. This factor is still the most powerful 
predictor of survival62, 63. The mitotic rate within the tumour is the average number of 
mitoses per millimetre squared and is also a significant prognostic factor64. Level of 
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invasion as defined by Clark et al.65 has been supplanted and is less commonly used for 
defining melanoma stages. The N category defines the number of micro or macro-
metastatic nodes determined by standard immunohistochemical staining against 
melanoma markers. The presence of intralymphatic metastasis, including the presence 
or absence of satellites or in-transit metastases, is also taken into consideration in this 
category. Regional nodal metastasis is defined as a disease confined to one nodal basin, 
while patients with distant nodal metastases will be classified as having M stage disease60. 
The M category defines the presence of distant metastases in the skin, subcutaneous 
tissue, or distant lymph nodes or organs. In addition, elevated serum lactate 
dehydrogenase (LDH) is an independent significant predictor of survival outcome among 
patients with distant metastases and has been included in this staging category66. 
Table 1. Classification of the pathological stage and the main features related to melanoma 
progression58. 
Pathologic 
Stage 
TNM 
Breslow’s 
Thickness 
(mm) 
Ulceration 
No. 
Positive 
Nodes 
Nodal 
Type 
Distant 
Metastasis 
Survival (%) 
5 
years 
10 
years 
0 Tis - No 0 - - 99+ 99+ 
IA T1a 1 No 0 - - 95.3 87.9 
IB T1b 1 
Yes/Level 
IV, V 
0 - - 90.9 83.1 
 T2a 1.01-2.0 No 0 - - 89.0 79.2 
IIA T2b 1.01-2.0 Yes 0 - - 77.4 64.4 
 T3a 2.01-4.0 No 0 - - 78.7 63.8 
IIB T3b 2.01-4.0 Yes 0 - - 63.0 50.8 
 T4a >4.0 No 0 - - 67.4 53.9 
IIC T4b >4.0 Yes 0 - - 45.1 32.3 
IIIA N1a Any No 1 Micro - 69.5 63.0 
 N2a Any No 2-3 Micro - 63.3 56.9 
IIIB N1a Any Yes 1 Micro - 52.8 37.8 
 N2a Any Yes 2-3 Micro - 49.6 35.9 
 N1b Any No 1 Macro - 59.0 47.7 
 N2b Any No 2-3 Macro - 46.3 39.2 
IIIC N1b Any Yes 1 Macro - 29.0 24.4 
 N2b Any Yes 2-3 Macro - 24.0 15.0 
 N3 Any Any 4 
Micro 
Macro 
- 26.7 18.4 
IV M1a Any Any Any Any Skin 18.8 15.7 
 M1b Any Any Any Any Lung 6.7 2.5 
 M1c Any Any Any Any 
Other 
Visceral 
9.5 6.0 
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Cutaneous melanoma can be subdivided into several subtypes, based on common 
anatomical locations and different patterns of growth67. Superficial spreading melanoma 
(SSM) is the most frequent, followed by nodular melanoma, acral lentiginous melanoma 
(ALM) and lentigo maligna melanoma (LMM)59. 
2.1.5 Genetic and histopathological changes in melanoma development 
Melanocytes progress to a malignant phenotype through several steps, in a process 
known as melanomagenesis68 (Figure 4). 
Both genetic predisposition and exposure to environmental agents are risk factors for 
melanoma development. However, the critical factor that takes place during this 
malignant transformation is the progressive accumulation of mutations in genes that 
target important pathways of cell proliferation, differentiation, and cell death (Table S1 
and Figure S1)69, until finally, melanoma cancer cells acquire the ability to initiate and 
sustain angiogenesis. 
 
Figure 4. Biologic events that take place in melanoma progression. The benign nevus commences 
a dysplastic transformation, through radial and vertical growth until the metastatic phenotype 
arises2. 
The Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signal transduction 
pathway is one of the most important pathways in the origin and progression of 
melanoma. BRAF is a member of the Raf family of serine-threonine kinases, along with 
ARAF and CRAF (also called RAF1). Mutations in the BRAF gene have been described in 
40-60%70, 71 of all melanoma cases. Among mutations in the BRAF gene, 80% of the 
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mutations result in the substitution of glutamic acid (E) for valine (V) in codon 600, 
known as the BRAF V600E mutation; about 16% of mutations in this gene result in a lysine 
(K) substitution at the same BRAF V600K codon, and 3% result in an aspartic acid (D) or 
arginine (R) substitution that produces a V600D/R codon72. These last two mutant forms 
of BRAF tend to be present in melanomas arising in older patients73. All of these mutations 
occur as early events in melanomagenesis and result in a mutant protein that is 
constitutively active in the cell without the need for activation signals. The consequence 
is uncontrolled proliferation and resistance to apoptosis. Nevertheless, the presence of 
BRAF mutations in 80% of benign nevi suggests that mutational activation of the MAPK 
pathway is a critical step in melanocytic transformation, but alone is insufficient for 
melanoma tumourigenesis74. 
Mutations in the NRAS gene are present in approximately 15 to 20% of all cutaneous 
melanomas75. Tumours that carry NRAS mutations represent a distinct subpopulation, 
since BRAF and NRAS mutations generally occur mutually exclusively76, 77. Together, 
NRAS and BRAF mutations are present in about 70% of the most common types of 
melanoma78. In addition to these mutations, melanomas (mostly acral melanomas) may 
carry mutations that activate the KIT receptor protein tyrosine kinase. The KIT gene is 
located on the long (q) arm of chromosome 4. Most KIT mutations are located in exon 11, 
which encodes for the juxtamembrane domain, and in exon 13, which encodes for a 
kinase domain79. 
2.1.6 Treatment and prognosis 
The standard treatment for in situ and primary melanoma is wide local excision (WLE) of 
the skin and subcutaneous tissues around the melanoma. Removing the melanoma from 
the skin by surgery offers the best chance for a complete cure, and this treatment alone 
is usually successful in patients categorised as stage 0, I and stage II (71% of all 
patients59). Most patients do not need either radiotherapy or chemotherapy, since the 
tumour is still localised and metastasis has not been diagnosed. Nevertheless, greater 
tumour thickness is associated with an increased risk of local recurrence80. WLE is the 
treatment of choice in local recurrences, with consideration given to adjuvant therapy in 
some situations59, since there is a risk of systematic or regional metastasis. 
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A sentinel lymph node biopsy is a recommended test for stage II patients with thicker 
tumours, to see whether a small number of melanoma cells have spread to the nearest 
lymph nodes81. If this procedure has positive results, the patient will be diagnosed with 
melanoma stage III. Since patients with positive lymph nodes are at high risk for systemic 
dissemination, a therapeutic lymph node dissection may be considered. 
 
Figure 5. Survival rates for patients with melanoma stages I through IV59. 
In summary, in regards to prognosis, the main clinical and histopathologic predictors of 
outcome are Breslow’s thickness, the presence of ulceration, the sentinel lymph node 
(SLN) status58 and the presence of distant metastases. Patients diagnosed with different 
stages have large differences in their survival rates (Figure 5). Unfortunately, for patients 
diagnosed with stage III and IV melanoma, the overall 5 and 10 years survival rates are 
drastically reduced relative to those with stages I or II (Table 1). 
2.2 Metastatic Melanoma 
Approximately 20% of all melanoma patients develop metastases within the first 2 years 
of diagnosis2. The typical sites of metastatic disease are the lungs, brain, skin, bone and 
liver82. Despite remarkable advances in the treatment of patients with metastatic spread, 
only 20% show long lasting responses (>2 years) to current treatments83, 84. 
The metastatic process starts with the vertical growth-phase of tumour development 
when melanoma cells penetrate the basement membrane, reaching the adjacent dermis 
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containing blood vessels and lymph, through which they then spread to form metastases 
at a distant location85. Modifications in surface protein expression profiles allow the 
detachment of melanoma cells from the primary tumour and provide the ability to 
metastasise2. The most important change in cell surface proteins is the loss of E-
cadherin/CDH1 and the expression of N-cadherin/CDH2. This transition triggers 
alterations in cell adhesion properties86. N-cadherin assists metastatic spread by 
allowing melanoma cells to interact with endothelial cells present in the stroma, which 
also express N-cadherin and this interaction increases the survival and migration of 
melanoma cells87. These alterations indicate the radial-growth phase to vertical-growth 
phase transition which is associated with changes in expression of metastasis initiation 
genes that allow these tumour cells to migrate and enter blood vessels (intravasation) 
(Figure 4)88, 89. 
In the next metastatic step, tumour cells can extravasate into distal tissues due to their 
low E-cadherin expression levels. Their entry can also be mediated by Rac activation90. 
When Rac is activated, the melanoma cells can changes shape and pass between adjacent 
cells, assisted by matrix metalloproteinases, which destroy integrins91. 
Metastasis progression genes allow melanoma cells to spread to distant organs. These 
cells are predominantly apoptotic and necrotic with a relatively short survival time in the 
blood of patients with several types of cancer. Immune cells present in blood can prevent 
almost all these cells from producing a secondary colony, except the most proficient92. 
These tumour cells, released from the primary tumour, extravasate into distant tissues 
where they finally develop a secondary tumour when the microenvironment is adequate 
(Figure 6). The extravasated cells are commonly found in clusters, covered by 
immunologically active cells, such as monocytes or leukocytes, and platelets that may 
play a critical role in CTC survival/destruction93,94. 
Once melanoma cells arrive at target tissues, cancer cells commence new organ 
colonisation and it is thought that, due to their neural crest origin, melanocytes retain 
some embryonic plasticity, contributing to their high metastatic potential95. The short 
latency of metastatic relapse suggests the existence of multi-organ metastatic 
competency in the malignant cells96. Nonetheless, metastatic disease can occur even 10 
years after an initial primary lesion97. 
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Despite the new advances in understanding metastasis in cancer, the pathways that 
melanoma cells use to metastasise are still unclear. Therefore, studies involving 
melanoma cells that invade and colonise new organs and tissues will unmask the cellular 
and molecular mechanisms underlying the metastasis of melanoma tumours. 
Currently, available tools to predict or detect metastatic spread in melanoma are 
relatively insensitive, which results in late detection of metastatic disease, significantly 
decreasing prognosis and survival. If patients with residual disease that might require 
treatment post-surgery were able to be identified earlier, treatment may be more 
effective when disease burden is lower4, 98. 
 
Figure 6. Melanoma metastatic process. Metastatic tumour cells detach from the primary site and 
penetrate the adjacent parenchyma to reach the blood vessels, adhering to secondary sites such 
as the brain, forming new colonies99. 
2.2.1 Progression 
Metastatic melanoma can be classified into local recurrence, in transit metastasis, nodal 
metastasis and distal metastasis, based on the location of metastases. 
Local recurrence is defined as a recurrence of melanoma within 2 cm of the surgical scar 
of a primary melanoma100. This recurrence can result either from extension of the 
primary melanoma, or from the spread via lymphatic or haematogenous vessels101. In 
transit metastasis is defined as melanoma deposits within the lymphatic vessels located 
more than 2 cm from the site of the primary melanoma. Nodal metastasis involves the 
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spread of tumour cells into the lymph nodes. Haematogenous spread of metastatic 
melanoma results in development of distal metastasis82. 
A variety of sophisticated imaging techniques are used to follow and evaluate patients 
with melanoma, including chest radiographs, regional nodal ultrasound imaging, 
computerised tomography (CT) scans, positron emission tomography (PET), PET/CT 
scans, and brain/spine and hepatic magnetic resonance imaging (MRI) to detect nodal 
disease and distal metastases59, 102. However, such technologies are relatively insensitive 
and unable to detect micrometastases59. There is therefore, a special need for sensitive 
methods that detect serological markers in patients likely to develop distant metastases 
and new biomarkers are being studied103, 104. At present the AJCC staging system only 
includes LDH blood levels as a prognostic marker for patients with stage IV disease62, and 
a more sensitive marker of residual disease is required. 
2.2.2 Treatment and prognosis 
The choice of therapy for the management of metastatic melanoma depends on the 
number of lesions, their anatomical location, and their size. The aims of treatment for 
metastatic melanoma are to control the melanoma and to relieve any symptoms, with 
curable intentions. Treatments that may be offered include surgery, radiotherapy, 
targeted therapies, chemotherapy, immunotherapy and diverse clinical trials of these and 
other new drugs individually or in combination are underway. 
New combinatorial drug development using targeted therapy and immunotherapy have 
revolutionised the clinical management of melanoma patients, improving the quality of 
life and the length of survival of patients with stage III or stage IV melanoma105-107. 
Nowadays, targeted therapies and immunotherapies are within the standard treatment 
choices for metastatic melanoma in Australia and several other countries108. 
Targeted Therapy 
Since the discovery of activating mutations in the BRAF oncogene in approximately 50% 
of melanomas70, there has been notable progress in the development of targeted 
therapies for unresectable and metastatic melanoma. The American Food and Drug 
Administration (FDA) has now approved the use of BRAF inhibitors vemurafenib and 
dabrafenib routinely109 for BRAF positive melanoma. These targeted treatments act as a 
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direct inhibitor of BRAF, which is constitutively active due to the presence of mutant 
copies of the BRAF gene and thus activates the MAPK pathway regulating tumour growth 
gene70. 
More recently, MEK inhibitors such as trametinib are administrated in combination with 
BRAF inhibitors110. Current clinical trials are testing different combinations of dabrafenib 
or vemurafenib with MEK inhibitor drugs as trametinib or cobimetinib111, respectively. 
Mutations in NRAS lead to up-regulation of heterogeneous effector pathways, thus 
making drug development more difficult and no standard drug is currently available for 
patients that carry NRAS mutations. However, new drugs are under investigation in pre-
clinical and clinical trials for NRAS inhibition as well as for alternative BRAF or c-kit 
mutations3, 112.  
Targeted therapy is effective in most patients. Unfortunately, despite the impressive 
initial tumour shrinkage, targeted therapy treatment responses are relatively short-lived 
and acquired resistance occurs in a high proportion of cases109, 113. Another disadvantage 
of this type of therapy is that significant toxicities are associated with BRAF inhibitors114 
and with combination therapies112, 115. 
Immunotherapy 
Immunotherapy is a promising cancer therapy that aims to strengthen anti-tumour 
response in patients with stages III or IV malignant melanoma. In 2011, the FDA approved 
the use of immune checkpoint inhibitor, ipilimumab for unresectable or metastatic 
melanoma. This antibody binds to cytotoxic T-lymphocyte antigen 4 (CTLA-4) on tumour 
cells and blocks its activity, allowing immune cells to target the melanoma cells. 
Unfortunately, the patient response rate is low (11.9%) and immune-related adverse 
effects are severe and common116. 
Alternate immune attenuating checkpoints have been studied and the interaction 
between programmed death-1 factor (PD-1) with its ligand (PD-L1) on diverse cells, such 
as, antigen presenting cells (APC) or tumour cells, is now routinely targeted for the 
treatment of metastatic melanoma107, 117. Pembrolizumab and nivolumab are anti-PD-1 
antibodies approved by FDA for the treatment of advanced melanoma in BRAF negative 
melanomas or after the failure of previous treatments118, 119. Anti-PD-1 blockade 
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antibodies are now available as first line therapy in BRAF-mutant negative melanoma 
patients. The response rate of melanoma patients to nivolumab, and pembrolizumab are 
43.7% and 33.7% respectively106, 120. Also, new immune checkpoints inhibitors as well as 
the combination of current immune therapies, such as ipilimumab/nivolumab or 
pembrolimumab/ipilimumab are being trialled121-123. 
Biomarkers 
Current therapeutic options for late stage disease are more effective when the disease is 
treated in patients with a lower disease burden124, 125. Consequently, melanoma must be 
treated at earlier stages to maximise the chances of patient survival. Thus, the ability to 
identify signs of melanoma progression prior to overt metastatic disease would be a 
valuable clinical tool. The rapidly evolving clinical landscape of melanoma therapy 
urgently requires the discovery and the development of reliable and accurate biomarkers 
that assist in early detection, diagnosis, staging, prognosis as well as prediction, and 
monitoring of treatment response. Also, biomarkers could improve the process of drug 
development and response prediction126. 
Biomarkers are classified as serum or tissue-specific biomarkers. Several serum 
biomarkers have been shown to have prognostic relevance in melanoma. One such 
marker routinely used is the enzyme lactate dehydrogenase (LDH) which has been shown 
to have prognostic value in later disease stages, and is incorporated in TNM 
classification127. However the sensitivity of this marker is reduced during progression128. 
Tyrosine and vascular endothelial growth factor (VEGF) were initially reported to have 
prognostic value129, 130. Subsequent studies could not confirm these findings and no 
prognostic value is attributed to them. Other diagnostic and prognostic serum 
biomarkers are osteopontin131, YKL-40 glycoprotein132, melanoma-inhibitory activity 
(MIA) protein133, s100 family protein134 and interleukin-8 (IL-8)135. However, none of 
these are commonly utilised in clinical settings. 
Tissue specific biomarkers for melanoma are molecules that are over-expressed in 
melanoma lesions. Cyclooxygenase-2 (COX-2) is an essential protein in catabolic 
metabolism. This protein is induced in tumour cells and a correlation between COX-2 
over-expression and Breslow thickness has been found in primary tumours136. Cell 
adhesion molecules and matrix metalloproteinases also play an important role in tumour 
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progression85. Chondroitin sulphate proteoglycan 4 (CSPG4/HMW-MAA/MCSP) is over-
expressed in over 80% of all melanomas and recent studies indicate that the protein is 
potentially valuable as a marker of response to treatment or progression137. Currently, 
different immune molecules associated with tumour inflammation, such as Galectin-3 
may be used to monitor treatment response in melanoma patients138. The prognostic 
utility of novel melanoma biomarkers, such as ctDNA, exosomes, or miRNA have been 
evaluated with promising results, although none have yet been clinically utilised. 
Although ctDNA measurements have been utilised in early detection of melanoma and in 
monitoring treatment response, there is a need to find additional biomarkers that can aid 
in measuring the disease load and treatment responses. Therefore, the need for 
melanoma biomarkers with the ability to provide information early during treatment are 
of critical importance when the patient is undergoing systemic treatment. 
For patients with advanced melanoma as well as those with localised disease, the analysis 
of circulating tumour cells (CTCs) may provide a novel biomarker to guide therapeutic 
decisions. Detailed molecular characterisation of melanoma cells circulating in the 
bloodstream may yield new insights into the process of melanoma metastasis139. 
2.3 Circulating tumour cells (CTCs) 
During the last decade, circulating tumour cells (CTCs) have received extensive attention 
as new biomarkers. On average, 20 new publications were published each week in 2013 
under the key phrase “circulating tumour cell”10, and the number of publications has 
continued to increase since then. 
The presence of tumour cells circulating in the blood of cancer patients was first reported 
by Thomas Ashworth in 1869140. It was observed that these cells were identical to the 
cancer cells found in the tumour, leading to the idea that these cells relate directly to 
neoplastic development and tumour metastases. The first detection of CTCs was made by 
B. Smith141 when technologies had evolved to permit the study of these rare cells. 
Circulating tumour cells (CTCs) are cancer cells which detach from primary or metastatic 
sites, enter the peripheral blood stream, and may develop into a secondary tumour at 
distant sites due to their capacity to enter and exit the bloodstream (Figure 7)82, 142, 143. 
However, only a small fraction of CTCs survive, since they have to escape from immune 
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system attack and survive in stressful ambient conditions without cell-matrix 
interaction9. CTCs have shown stem-like properties, which might facilitate initiation of 
metastatic lesions144, 145. Interestingly, these cells can enter into a state of clinical cancer 
dormancy, where, after dissemination, cell division processes may stop and the cell may 
persist in a quiescent state, sometimes for more than 10 years146. The amount of time 
involved in the dormancy process varies among different kinds of cancers, being 
generally relatively short in melanoma (1-2 years)82, although this may vary. CTCs show 
malignant features147 not present in healthy cells, and may have less genomic alterations 
than primary tumour cells, suggesting that the dissemination may happen in earlier 
stages of the disease148. 
 
Figure 7. Metastatic cascade149. 
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2.3.1 Biomarker value of CTCs 
Circulating tumour cells are derived from the primary and metastatic tumours and their 
study provides significant information about the biology and development of the tumour. 
Since these cells can be isolated from blood using relatively non-invasive approaches, 
their presence in peripheral blood can serve as a “liquid biopsy”. As an independent 
prognostic marker, the number of CTCs before, during and after therapy administration 
has been shown to be an indication of the length of progression free survival (PFS) and of 
overall survival (OS) in various cancers8, 9, 150. 
The utility of CTCs as biomarkers for the prognosis and in the monitoring of response to 
anticancer therapies has been widely reported for several types of solid cancers. In breast 
cancer, CTCs have indicated prognostic value151, 152. Several studies in ovarian cancer 
have shown the utility of CTCs in disease monitoring153, 154 with elevated numbers of CTCs 
indicating an unfavourable prognosis155. Similar results have been found in other cancer 
types such as prostate6, lung156, colorectal157, and hepatocellular carcinoma158. Several of 
these studies have used the CellSearch® system (Veridex LCC), the only FDA-approved 
CTC enumeration test, which exploits CTCs as a new parameter for estimating prognosis 
and monitoring treatment success in metastatic breast, colorectal, and prostate cancer159-
161. 
2.3.2 Biomarker value of CTCs in melanoma 
While additional studies are required to further characterise melanoma CTCs and 
confirm their clinical utility as a biomarker of treatment response, monitoring the levels 
of CTCs before and during melanoma treatment has been shown to be informative with 
respect to prognosis and therapy response in melanoma patients. 
RT-PCR has been widely used to detect mRNA transcripts associated with melanoma in 
blood. Reid et al., examined whole blood RNA from 230 melanoma patients and showed 
that the presence of MLANA and ABCB5 transcripts was associated with disease 
recurrence and the expression of MCAM was significantly more common in patients with 
a negative treatment outcome162. Also, the presence of multiple melanoma markers in 
patient blood significantly correlated with their AJCC stage163; the detection of more than 
 
20  2. LITERATURE REVIEW 
one marker at baseline and at any time during treatment administration was a negative 
prognostic factor for disease-free survival (DFS) and for overall survival (OS)164. 
Several studies using immunomagnetic bead-based isolation techniques have also shown 
that the number of melanoma CTCs is higher in the blood of patients with advanced 
disease4, 165-167. The number of CTCs was also shown to be associated with treatment 
failure and shorter median OS if ≥ 2 CTCs are found per 7.5 mL during the time that 
patients are receiving treatment168, 169. By contrast, a low CTC count at baseline (< 2 CTCs) 
or a decrease in CTCs after treatment initiation was associated with response to 
treatments and longer progression free survival (PFS) rates98. 
More recently, Gray et al, showed that the presence of CTCs was associated with PFS170. 
Interestingly, early-stage patients were generally positive for a single marker compared 
to late-stage patients who had larger numbers of CTCs expressing a variety of markers. 
Remarkably the differential pharmacodynamic response of CTC subtypes to treatment 
was evident in patients treated with BRAF inhibitors (n=16), since the proportion of CTCs 
expressing RANK were significantly increased after therapy. In addition, patients with 
more than 5 RANK+ CTCs in 4 mL of blood had significantly lower PFS than those with 
less than 5 or no RANK expressing CTCs170. Similarly, a preliminary study showed that 
the presence of CTCs expressing PD-L1 was associated with response to anti-PD1 
blockade171. Thus, prognostic utility might be found not by using total CTCs counts but by 
studying specific subpopulations of CTCs. 
New experiments with patient-derived xenografts (PDX) are providing new information 
that can inform treatment decisions for each patient. Alternately, where tumours are 
inaccessible, CTC-derived xenografts or in vitro growth of CTCs may provide a powerful 
option for testing of drug efficacy in a patient’s cells. Girotti et al, showed that CTC-
derived xenografts (CDX) established from advanced stage patients could aid in 
monitoring and predicting patient responses to treatments. In fact, they have been 
successful in generating CDXs in 6 out of 21 cases (28.6%)172. While the isolation of only 
a few CTCs capable of developing xenografts may underestimate the tumour 
heterogeneity, these are excellent first steps to addressing several of the issues 
surrounding the clinical benefit of CTC characterisation, including the fact that CTCs that 
develop xenografts are capable of seeding metastases and therefore harbor significant 
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information about the metastatic process. Additionally, further studies characterising 
CTC subpopulations prior to injecting them into mice will provide crucial information 
about CTC phenotypes that are most likely to develop CDXs. 
2.4 Methods for the isolation and detection of melanoma CTCs 
The enrichment and detection of CTCs from melanoma patients is extremely challenging, 
mainly due to the limited amount of sample available and the very low concentration of 
these cells in the peripheral blood, roughly 1 CTC in 106 normal blood cells. In addition, 
for melanoma, the difficulties are magnified because common CTC markers, such as 
EpCAM, used in CTC enrichment of epithelial cancers, are not commonly expressed by 
melanoma CTCs, since melanocytes originate from the neural crest and not the 
epithelium173. In fact, melanomas CTCs are a very heterogeneous population of cells4, 170, 
174, yet current techniques used to enrich melanoma cells from blood, commonly do not 
consider this fact. 
Assays used for CTC identification and characterisation (Figure 8) usually require a 
combination of enrichment and detection procedures that aim firstly to increase the 
concentration of CTCs in a background of white blood cells and secondly, to enable easier 
detection and characterisation of single cells. Despite the actual advances in CTC isolation 
and detection technologies, the enrichment of pure CTCs from patient blood remains the 
most challenging step to date. 
 
Figure 8. Melanoma CTC isolation and detection technologies. 
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2.4.1 Isolation techniques in melanoma 
Isolation technologies take advantage of the biological and physical properties of the 
CTCs. Biological properties, such as cell surface protein expression, can be useful 
characteristics for the isolation of tumour cells from peripheral blood of cancer patients. 
On the other hand, cell size, density, total electric charges, and deformability are now the 
main physical characteristics used in CTC enrichment175, 176. Thus, CTC isolation assays 
can be grouped into label-dependent and label-independent methods177, each method of 
enrichment having different advantages and disadvantages (Table 2). These methods are 
detailed below. 
Table 2. Advantages and disadvantages of the label-dependent and label-independent isolation 
methods. 
 Label-dependent methods* Label-free methods 
A
d
v
a
n
ta
g
e
s 
Lower WBC Background 
Do not rely on the expression of surface 
markers for CTC isolation 
Most commonly used Integrity of the membrane not affected 
The only FDA-approved method for isolation of 
CTCs uses this technology 
Viability of the cell is maintained 
 
More heterogeneous population of CTCs is 
isolated 
 High recovery efficiency 
 
Huge heterogeneity in the population of 
CTCs isolated 
D
is
a
d
v
a
n
ta
g
e
s 
Low heterogeneity in the population of CTCs 
isolated 
Not widely used in CTCs isolation. More 
study is needed 
Alteration of membrane integrity Higher WBC Background 
Viability of CTCs is affected  
Only CTCs expressing the targeted biomarker are 
isolated 
 
*Excluding Negative Immunomagnetic Enrichment 
Label-dependent methods 
Despite the demonstrated heterogeneity of melanoma CTCs170, 174, 178, methods for 
capture and enrichment of melanoma CTCs have to date relied predominantly on the 
expression of one or two known cell surface markers. For example, immunomagnetic 
enrichment using magnetic beads coupled with antibodies against known melanoma-
specific antigens have been developed to enrich CTCs (positive selection). Alternate 
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methods that deplete white blood cells using beads targeting common leukocyte (CD45 
or CD34) antigens (negative selection) have also been widely used168, 169, 179, 180. 
The CellSearch™ system (Veridex LCC) is the only FDA-approved CTC enumeration test. 
This platform involves immunomagnetic bead capture of CTCs followed by cancer-
specific marker staining for CTC detection. For breast, prostate and colorectal cancer, 
EpCAM is used to capture CTCs followed by staining with cytokeratin150, 181-183. For 
melanoma, however, a different CellSearch™ kit was developed that firstly captures CTCs 
expressing melanoma cell adhesion molecule (MCAM) from whole blood and secondly 
detects CTCs by immunostaining with anti-MCSP (melanoma-associated chondroitin 
sulphate proteoglycan). This kit also immunostains CD45 and CD34 positive cells to 
exclude leukocytes and endothelial cells. Khoja and colleagues168 used this melanoma 
specific CellSearch™ kit to detect CTCs in 101 metastatic melanoma patients, and found 
0-36 CTCs/7.5 mL of blood at baseline prior to treatment, with 60% of patients having no 
CTCs and 40% of patients with at least one detectable CTC. Similarly, Rao et al., found 0 
to 8,042 CTCs/7.5 mL of blood in 44 melanoma patients: 23% of the patients had two or 
more CTCs169. 
The need to better capture all melanoma CTCs has driven the development of multiplex 
assays where beads linked to cocktails of antibodies against both cancer-related markers 
and melanoma-specific cell surface antigens are used. 
Freeman and colleagues4 found that using a combination of MCSP, MCAM, ATP-binding 
cassette sub-family B member 5 (ABCB5), and cluster of differentiation 271 (CD271) 
targeting antibodies captured a significantly higher number of melanoma CTCs in 
metastatic melanoma patients than did the use of MCSP or MCAM alone. This finding 
demonstrated, for the first time, the high diversity of melanoma CTCs and improved the 
sensitivity of bead-based CTC enrichment compared with experiments that target single 
markers. Moreover, when using a combination of all of these labelled beads, stage I-II 
(n=10) and stage III-IV (n=13) patients showed significantly higher numbers of CTCs than 
controls (n=15). More than 1 CTC/mL of blood was detected in 73.9% of patients (range: 
0-2.5 CTCs/1 mL of blood). Despite the improvements in sensitivity produced by using a 
cocktail of antibodies for CTC capture, spiking experiments revealed that 
immunomagnetic enrichment still has low capture efficiency (34%)4. 
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In order to improve capture efficiency, a device has been developed more recently that 
uses micro-vortices generated by herringbone-shaped grooves to direct cells toward 
surface channels coated with a combination of antibodies targeting melanoma-specific 
antigens. One study using the herringbone-chip (HB-chip) technology with a combination 
of 12 antibodies against melanoma cell surface epitopes detected CTCs by 
immunostaining in 79% of patients (8 CTCs/2.5 mL) from a total of 41 metastatic 
melanoma patients at various stages of melanoma treatment165. 
To avoid capture bias, other methods use negative selection procedures, which capture 
leukocytes with anti-CD45 antibody coated beads followed by depletion of white blood 
cells using magnetic separation. Systems such as EasySep™ or RosetteSep™ use this 
approach. Fusi et al. using the EasySep™ method and detecting CTCs as cells expressing 
gp100 and MLANA (melanoma antigen recognized by T cells 1) by flow cytometry, found 
87.5% of 32 metastatic melanoma patients had CTCs with a median of 53 CTCs/10 mL of 
blood184. Using RosetteSep™, Girotti et al. successfully enriched CTCs and injected them 
into NSG mice to generate CDX models172. While the authors have not provided CTC 
quantities used to generate the models, it is likely that relatively large numbers of cells 
were isolated for successful tumour uptake. 
Although negative selection is advantageous for removing cells that do not express the 
most common melanoma markers, the purity of CTCs obtained in the enriched fraction is 
low, hampering the quantification of CTCs as well as limiting downstream analysis of the 
detected CTCs for prognosis. In fact, a spiking experiment comparing the recovery and 
purity of CD45 depletion, with positive enrichment, or a combination of both methods, 
showed that the greatest recovery was found by using negative selection (58% recovery 
rate). However, the greatest purity of the CTC fraction was obtained by using the 
combination method (background reduced from 3x107 to 1.5x103of WBCs)179. 
The targeting and capturing of CTCs using protein-based enrichment approaches as is 
most commonly performed, typically do not allow capturing all CTCs present within a 
patient and furthermore, the harsh conditions of the isolation techniques may alter the 
integrity and viability of CTCs185, 186, and hence, they are highly critical in functional 
studies. Methods that isolate CTCs with high purity, integrity and viability are urgently 
needed to determine the real biomarker potential of CTCs in prognosis and in the 
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prediction of therapeutic responses in metastatic melanoma patients. Thus, the 
development of label-free enrichment technologies is a promising alternative for the 
successful isolation of melanoma CTCs. 
Label-free methods 
To further improve CTC capture, alternative techniques have been developed more 
recently, that exploit the larger cell size of melanoma CTCs compared to the remaining 
white blood cells. Although it has been shown that melanoma CTCs can have a diverse 
range of cell sizes185, most of the CTCs are thought to be larger (10-20 µm) than other 
blood components, such as RBCs (6-8 µm), leukocytes (7-12 µm) or platelets (2-3 µm). 
Taking advantage of this perceived difference in cell size, the “enrichment by size of 
epithelial tumour cells” (ISET®) technique was developed in 2000187. The ISET® system 
uses polycarbonate filters with 8 µm diameter circular pores for CTC enrichment and 
detection of cells trapped in filters as CTCs involves immunohistochemical staining and 
PCR-based genetic analyses. De Giorgi et al. detected CTCs in 29% of patients with 
primary invasive melanoma and in 62.5% of metastatic melanoma patients using this 
microfiltration system followed by positive detection by real-time RT-PCR for tyrosinase 
transcripts. Experiments assessing the sensitivity of this assay showed that ISET® had a 
limit of detection of 1 CTC/mL of blood188. However, challengingly, this approach was also 
found to isolate benign circulating nevus cells189, suggesting that the molecular analysis 
of tyrosinase mRNA by RT-PCR-based systems, cannot reliably distinguish between 
benign nevus cells and melanoma cells. 
Nevertheless, when using the same ISET enrichment technique, with CTCs defined by 
positive immunohistochemistry expression of s100 and negative expression for CD45 or 
CD144 (leucocyte and endothelial cell markers, respectively), 57% of 90 metastatic 
melanoma patients had detectable CTCs (1-44 CTCs/mL of blood)174. 
The OncoQuick® system is another size-based technique that incorporates a filter for 
size-based separation of CTCs which is used in conjunction with density-based 
centrifugation190. Spiking experiments showed a ≥60% recovery rate when assessed by 
qPCR amplification of cytokeratin 8 (KRT8) and 18 (KRT18) RNAs, for 4, 20, 100 and 500 
spiked SkMel28 cells. When the OncoQuick® was used for isolation of CTCs from 
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melanoma patients, and target RNA transcript levels (MLANA, MIF, TYR, and MITF) were 
then quantified by qPCR, results showed that about 1/3 of patients expressed elevated 
levels of MIF and MLANA transcripts, in comparison with healthy controls (p<0.0001 and 
p<0.001, respectively)191. 
Microfluidics 
Microfluidic devices control microliter to milliliter volumes in micro-channels of 1 μm to 
1000 μm in size. In such conditions, the concentrations of particles/cells can be 
effectively controlled, since the flow is strictly laminar192, 193. 
At the beginning of the 21st century and the arrival of nanotechnology, many microfluidic 
components that work with nanoliter volumes were developed for use in biological 
studies194-196. Since then, the field of microfluidics has evolved rapidly, allowing the 
manipulation of DNA, RNA, proteins and mammalian cells, as well as single cell assays for 
disease diagnosis and prognosis, amongst several other applications193. At present, 
microfluidics are valuable for cancer cell investigations due to their high sensitivity, high 
throughput, low material consumption, low cost and improved spatial-temporal control. 
Microfluidic devices are now proving very useful for isolating CTCs from the blood of 
patients with different cancer types. 
To date very few studies have utilised microfluidic devices to isolate CTCs from 
melanoma patients. The more recently developed CTC-iChip (Figure 9) separates cells 
based on size selection using deterministic lateral displacement and inertial focusing 
followed by negative depletion in a magnetophoresis. Using this chip, CTCs from 
melanoma patients were successfully enriched and detected as positive by staining for 
the melanoma antigen recognized by T cells 1 (MART-1)185. 
Previous studies identified that CTCs exist as circulating tumour microemboli (CTM) or 
CTC clusters in the blood of melanoma patients, raising the idea that cells enter the 
bloodstream via collective cell migration, allowing them to survive shear stress and 
anoikis forces93, 174. Recently, the Cluster-Chip (Figure 9) was developed particularly to 
isolate CTC clusters178. The Cluster-Chip captures CTC clusters of two or more cells 
directly from 4 mL of blood, independently of cell tumour-specific marker expression. 
This microchip technology relies on the strength of the cluster union as well as on their 
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behaviour when a flow speed is applied through a set of triangular pillars. Captured CTC 
clusters were identified and detected by immunofluorescence staining in 30% (~0.15 
CTCs/mL) of 20 tested metastatic melanoma patients. Interestingly, no correlation was 
found between the number of CTC clusters isolated using the Cluster-Chip and the 
number of single CTCs isolated using CTC-iChip (n=19)178. 
   
Figure 9. The CTC-iCHIP (left) and Cluster-Chip (right) microfluidic CTC devices178, 185. 
Two new spiral microfluidic devices (A5 and Slanted) that allow CTC enrichment based 
on Dean Drag forces and the inertial microfluidic phenomenon, have been developed for 
CTC isolation11, 12. This separation technology is termed Dean Flow Fractionation (DFF), 
and allows a size-based separation using hydrodynamic forces and Dean Drag forces 
acting on cells within a laminar flow due to the curvilinear geometry of the 
microchannels. The Drag equation calculates the force of drag experienced by an object 
due to movement through a fully enclosing fluid. The microenvironment created by these 
forces causes different sized particles to travel at different speeds in the liquid phases 
with the result that each particle acquires different lateral positions and exhibits different 
degrees of focusing inside the chip, allowing a successful size-based separation. Cells are 
affected differently by these forces depending on their size, allowing separation through 
two different outlets (see Figure 11). Since the size of most of the CTCs are thought to be 
larger (10-20 µm)12, 197 than that of other blood components, the DFF-based method 
appears suitable for separation of these cell types. 
CTC isolation using spiral microfluidic devices that use Dean drag forces198 to separate 
tumour cells on the basis of their size11, 12, 199 were tested in this study for the isolation of 
melanoma CTCs. The big advantage of this method over label-based isolation techniques 
is that it isolates all CTCs regardless of their cell surface proteins. Moreover, there is no 
manipulation of cells, which can affect their viability, as well as downstream analyses185, 
186. 
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The Slanted microfluidic device 
The Slanted spiral microfluidic device relies on inertial microfluidic forces and Dean Drag 
forces to separate CTCs from blood cells. This device contains 8-looped spiral 
microchannels with one inlet for the sample and two outlets, one inner outlet for 
collection of the CTC-enriched cellular fraction (CTC outlet) and one outer outlet for 
collection of unwanted blood cells (waste outlet) (Figure 10). The operating principle of 
this chip allows large CTCs to stay near the inner channel wall and to be collected from 
the inner cell outlet of the chip. 
The trapezoidal geometry of the channel cross-section200 increases the resolution of the 
separation due to its influence on the formation of Dean vortex cores in the outer walls. 
This design is ideally effective when isolating particles with large diameter and low 
abundance from smaller and abundant particles. Accordingly, the enrichment of low-
abundant CTCs from other blood components is a satisfactory condition for this design. 
This Slanted microchip has been shown to efficiently capture cancer cells from blood cells 
when using cell lines (MCF-7, T24, and MDA-MB-231) spiked into whole blood. The 
results showed an isolation efficiency of ~85%, with a viability of captured cells of 
>90%11. High purity was also achieved (400-680 WBCs per mL; ~4 log depletion of 
WBCs).
       
 
 
 
 
 
 
Inner wall                      Outer wall 
    
Figure 10. Slanted microchip operating principles for CTC isolation. One inlet for the sample and 
two outlets for the enriched cells (CTC outlet) and for the other blood components (waste outlet). 
The trapezoidal section is represented as A-A11. 
Validation of this isolating principle has been performed in clinical samples. Five patients 
with metastatic breast cancer (MBC) and 5 patients with non-small cell lung cancer 
Waste          CTC           Sample 
Outlet         Outlet           Inlet 
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(NSCLC) were studied, as well as 5 healthy controls. All cancer patients had detectable 
CTCs (6-57 CTCs mL-1 for MBC and 3-125 CTCs mL-1 for NSCLC)11. 
A5 microfluidic device 
The A5 chip also relies on Dean Flow Fractionation (DFF) forces to isolate CTCs from 
blood. Due to the presence of Dean Forces and inertial lift forces in the curvilinear 
channels of the device, a more efficient, high resolution size-based separation is 
achieved12 (see Table 3). The microchip consists of 2 inlet and 2 outlet spiral 
microchannels of ~10 cm in length. The design of the chip allows larger CTCs to focus 
their position inside the channel and be collected through the inner CTC output, while 
smaller blood components, less affected by the Drag forces, are removed via the outer 
outlet. The blood sample is pumped into the sample inlet, and a sheath fluid is pumped 
into the sheath inlet at a higher flow rate. Once the sample is inserted into the device, the 
separation process is initiated, with the cells taking different positions inside the 
channels, allowing their separation into the outlet portals (Figure 11). 
The efficiency of this DFF device was validated using cancer cell lines cells spiked into 
whole blood. Three different cell lines (MCF-7, HeLa, and MDA-MB-231) were tested and 
a cell recovery of ~85% was achieved using spiked cancer cells. Also, a 2000 fold 
leukocyte reduction and a CTC/leukocyte purity of ~10% was achieved from ~2X 
dilution of whole blood with saline buffer. 
To test the efficacy of this device to isolate CTCs from blood, 20 metastatic lung cancer 
patients and 20 healthy controls were tested and CTCs were successfully detected in all 
cancer patients (5-88 CTCs/mL)12. The enrichment of CTCs from lung cancer patients 
demonstrated the high-throughput capability and high-sensitivity separation of CTCs 
using this device. 
Moreover, the label-free procedure and the purity of the output sample, allows a 
downstream analysis of the live retrieved cells, which include RNAseq, single-cell next 
generation sequencing (NGS), quantitative-PCR (q-PCR), FISH or immunofluorescence 
staining. 
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Figure 11. Optical image of the A5 spiral microfluidic device used in capturing CTCs. Two inlets 
for the sample and the sheath flow, and two outlets for the enriched cells (CTC outlet) and for the 
other blood components (waste outlet)12. 
Recently, a multiplexed version of the A5 chip, that combines three spiral circuits in the 
same chip199, has shown better detection of CTCs from breast and lung cancers than those 
detected with the FDA-approved CellSearch® method. CTCs were detected in 100% of the 
cancer patient samples (n=56), while CellSearch® only detected CTCs in 80% of the 
samples201. Furthermore, lower numbers of CTCs were obtained using the CellSearch® 
system201. The major advantage of the A5 chip compared to the CellSearch® method, is 
the capability of it to be used in different cancers, of both epithelial and non-epithelial 
origin, since this approach does not require initial cell surface biomarker selection. 
Table 3. Main characteristics of the two microfluidic devices used in this project. 
  Slanted chip A5 chip 
C
h
a
ra
ct
er
is
ti
cs
 
Number of inlets 1 2 
Number of outlets 2 2 
Viability test Yes (>90%)** Yes (>98%)** 
Processing time 1.1 min per 1 mL blood 20 min per 1 mL blood 
Flow rates 1700 μL min−1 sample inlet 
750 μL min−1 sheath inlet 
100 μL min−1 sample inlet 
Sample concentration 0.5x 0.5x 
Purity ~4 log depletion of WBCs ~3 log depletion of WBCs* 
Recovery rates > 85%** >85%** 
*From whole blood. **Using cell lines. 
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In this thesis, the ability of these two novel microfluidic chips to isolate melanoma cells 
and CTCs from metastatic melanoma patients was tested for the first time. Three different 
settings were studied, namely: single Slanted (1X Slanted), single A5 and double Slanted 
(2X Slanted). 
2.4.2 Detection techniques 
While the above techniques are utilised to isolate/enrich CTCs, optimisation of methods 
for the visualisation of the isolated CTCs is also required. A few methods that detect 
melanoma CTCs in whole blood from patients, without an enrichment step, have been 
reported. For example, Ruiz et al. describes the use of the Epic Sciences platform to detect 
intact melanoma CTCs. Erythrocyte lysis was followed by nuclear size analysis and 
immunocytochemical identification of melanoma CTCs using a panel of seven anti-MCSP 
monoclonal antibodies. Micromanipulation was performed to isolate single CTCs for 
whole genome amplification and copy number variation (CNV) analyses. This method 
detected 1-250 CTCs in 8 mL of blood (0.5 to 371.5 CTCs/mL of blood) from 22 of 40 
metastatic melanoma patients (55%). Interestingly, CNV analyses revealed deletions of 
CDKN2A and PTEN, and amplifications of TERT, BRAF, KRAS and MDM2 genes among 
others202. 
Currently, CTCs present in the enriched fraction are studied and detected by methods 
that assess their morphology and/or protein expression using immunocytochemistry 
(ICC) or flow cytometry. These techniques stain the cells with a cocktail of antibodies 
against cell surface or intracellular markers associated with melanocyte biology or 
melanoma pathogenesis4, 170, 203, 204. Cells are considered tumour cells if positively 
fluorescently stained for melanocytic markers, melanoma or tumour-specific markers, 
and for the nuclear dye (DAPI or Hoechst 33342), but negative for the common leukocyte 
antigen CD45 (a marker present only in leukocytes and not in tumour-derived CTCs). 
Using multicolour image analysis with a fluorescence microscope, CTCs are thus 
identified as melanocyte/melanoma markers+/CD45-/DAPI+ cells (Figure 12). 
In addition, molecular approaches that detect RNA or DNA from enriched melanoma 
CTCs, by quantitative real-time PCR (qRT-PCR)205 or droplet digital PCR (ddPCR)206 
respectively, have been used for CTC detection and more detailed CTC characterisation. 
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New methods based on the presence of elevated telomerase activity are being trialled for 
CTC detection207. 
 
Figure 12. Immunofluorescent CTC staining. 
Gray et al. has recently developed a flow-cytometry multimarker approach to detect and 
analyse CTCs for the presence of melanoma-associated markers, such as MCSP and 
MCAM, in combination with melanoma stem cell markers, such as ABCB5, RANK 
(receptor activator of NF-κβ) and CD271170. Using this approach we provided for the first 
time, a detailed insight into the diversity of melanoma CTCs, and showed that the 
prognostic utility of melanoma CTCs may not rely on the total count of CTCs but on the 
CTC subpopulations circulating within an individual. This study indicated that a high 
number of melanoma CTCs express melanoma-initiating or stem cell markers (ABCB5 
and RANK) while only a very low number of CTCs express melanoma markers MCSP and 
MCAM170. Importantly, this study also observed that the common expression of these 
melanoma-initiating markers by melanoma CTCs did not correlate with the expression of 
these markers in patient-matched tumours, where a rare frequency of melanoma tumour 
cells positive for these markers was observed. This finding provides evidence supporting 
the hypothesis that CTCs, at least in in melanoma, are derived from rare subpopulations 
present in the tumour, which might have the ability to seed new metastases, and not from 
the bulk melanoma cells shaping the tumour170. 
In summary, the use of microfluidic devices to isolate highly heterogeneous melanoma 
CTCs independently of their marker expression could be beneficial. Additionally, the 
MELANOMA 
MARKERS 
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application of multimarker immunostaining protocols for the detection of CTCs in the 
enriched fraction is of vital importance. Table 4 shows eight of the most common tumour 
and melanoma-specific markers used in immunological detection of melanoma. 
Table 4. Markers commonly used in immunological detection procedures in melanoma. 
Marker Name or encoding gene References 
Cellular 
location 
gp100 
Also known as premelanosome protein (PMEL), silver locus 
protein homolog (SILV), ME20, or Pmel17. 
208 Cytosol 
MART1 
Melanoma antigen recognized by T cells 1. Also known as 
Melan-A protein. 
52, 209, 210 Cytosol 
s100 Different types encoded by the s100b(number) genes. 51, 210 Cytosol 
MCSP 
Melanoma chondroitin sulphate proteoglycan. Also known as 
chondroitin sulfate proteoglycan 4 (CSPG4) or neuron-glial 
antigen 2 (NG2). 
169, 203, 211 Membrane 
Vimentin 
This protein is a type III intermediate filament expressed in 
mesenchymal cells, encoded by the VIM gene. 
212-214 Cytosol 
RANK 
Receptor activator of nuclear factor κβ. Also known as 
TRANCE Receptor or TNFRSF11A. 
4, 170, 215 Membrane 
ABCB5 
ATP-binding cassette sub-family B member 5. Also known as 
P-glycoprotein ABCB5. 
4, 170, 216 Membrane 
In this study, we developed and optimised a protocol for improved staining of CTCs that 
utilises three internal markers (gp100, MART1/Melan-A, and s100) and one cell surface 
marker (MCSP) to identify CTCs isolated from patient blood using the microfluidic 
devices. Lastly, based on Gray et al. findings which show a high number of melanoma CTCs 
express the melanoma-initiating or stem cell markers, we have incorporated ABCB5217, 
RANK170 and Vimentin213 into our panel, to improve the detection and characterisation of 
CTCs after spiral microfluidic enrichment in future studies. 
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3. THEORETICAL FRAMEWORK 
New biomarkers are required for the early detection of disease progression and 
therapeutic response in metastatic melanoma patients. Circulating tumour cells (CTCs) 
have been shown to be a useful biomarker of cancer development and for therapeutic 
response guidance16, 218, 219. However, isolation of melanoma CTCs is very challenging 
because of the low quantities of CTCs in blood and the heterogeneity of cell surface 
markers expressed by melanoma CTCs10, 170, 174. These challenges have limited the utility 
of CTCs as biomarkers in patients with metastatic melanoma. 
Microfluidic chips can successfully isolate CTCs with high integrity from different cancer 
types11, 199, 201, with few used in melanoma to date178, 220. The ability of microfluidic 
devices to isolate label-free and viable CTCs with high efficiency and low cost has 
prompted their use in this study for isolation of heterogeneous melanoma CTCs170. 
The detection of CTCs using melanoma-specific markers has previously indicated the 
extreme heterogeneity of these cells170, 174, 220. To better understand their biology and the 
differential response of heterogeneous CTCs to treatment, immunostaining protocols that 
combine multiple cancer, melanocyte and melanoma-specific markers are developed and 
optimised here to assist with detection of diverse CTC subpopulations isolated from 
metastatic melanoma patients using a label free device4, 170. 
The optimisation of live and label-free CTC isolation procedures using available 
microfluidic devices as well as the optimisation of approaches for the detection of a broad 
spectrum of CTC subtypes from metastatic melanoma patients is of importance for the 
study of melanoma progression and therapeutic efficacy. 
The overall aim of this study was to determine the effectiveness of the isolation of 
melanoma cell lines using three microfluidic approaches (1X Slanted11, A512 and 2X 
Slanted), and the potential for these devices to be utilised for the isolation of pure CTCs 
from the blood of metastatic melanoma patients. Furthermore, the study aimed to assess 
additional cellular markers to be used in immunostaining that can improve the detection 
of CTCs isolated from melanoma patients using microfluidic devices. The implementation 
of this label-free method in isolating CTCs will facilitate downstream functional studies 
as well as phenotypic and genomic characterisation of melanoma CTCs. 
 
35 3. THEORETICAL FRAMEWORK 
3.1 Hypothesis 
Spiral microfluidic devices allow the isolation of circulating melanoma cancer cells 
(CTCs) from the blood of metastatic patients. 
3.2 Aims 
1. To measure the efficiency of three spiral microfluidic approaches to isolate differently 
sized melanoma cell lines spiked into healthy control blood. 
In order to determine for the first time the ability of the spiral microfluidic devices to 
isolate melanoma cells, spiking experiments were performed to compare the recovery 
rates after processing through single Slanted (1X Slanted), single A5 and double Slanted 
(2X Slanted). The recovery efficiency and purity were analysed for each method. 
2. To detect CTCs from metastatic melanoma patients enriched by the 2X Slanted device, 
using an optimised immunostaining protocol. 
After enrichment through the 2X Slanted device, protocols for detection of CTCs from 
patient samples, such as cytospin conditions and immunostaining were optimised. Blood 
samples from 10 metastatic melanoma patients were then analysed for the presence of 
CTCs after enrichment using the 2X Slanted microfluidic device, followed by the revised 
immunostaining protocol. In addition, 3 healthy volunteers were used as negative 
controls. 
3. To test additional cellular markers that can be used in immunostaining assays for 
optimisation of detection and phenotypic characterisation of heterogeneous melanoma 
CTCs. 
In order to further improve the detection of CTCs, three additional cancer stem-cell and 
tumour markers were tested, Vimentin, RANK, and ABCB5. To assess their ability to 
improve CTC detection, the expression of these markers was assessed by 
immunocytochemistry in three melanoma cell lines, either alone or when spiked into 
blood from healthy volunteers. 
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4. METHODS AND MATERIALS 
4.1 Aim 1. To measure the efficiency of three spiral microfluidic 
approaches to isolate differently sized melanoma cell lines spiked into 
healthy control blood. 
4.1.1 Experimental Design and Methods 
Figure 13 illustrates the key steps followed in the preparation and processing of the 
samples in order to determine the efficiency of different spiral microfluidic approaches 
to isolate spiked melanoma cells with different cell sizes spiked into blood samples from 
healthy donors. For this, three microfluidic approaches were used: single Slanted (1X 
Slanted), single A5 and double Slanted (2X Slanted), by which the sample is processed 
twice through the Slanted device. The last setting was tested with the aim of improving 
WBC depletion rates. 
 
 
Figure 13. Overview of the methodology of sample preparation and processing. Firstly, the 
spiking of melanoma cells into healthy blood samples was completed (A) prior to processing the 
blood using three different approaches (B). Finally, the recovery analysis (C) determined the 
recovery rates for each spiral microfluidic approach by counting total red labelled cells recovered 
in the enriched fraction. 
Cell lines and cell culture 
Two melanoma cell lines (A2058 and SKMEL5) obtained from the American Type Culture 
Collection (ATCC, USA) were used in spiking experiments. Previous studies in our 
research laboratory have identified melanoma cell lines A2058 and SKMEL5, as the cell 
lines with the smallest and largest cell size respectively, from a panel of six melanoma cell 
lines (Figure 14). 
 
37 4. METHODS AND MATERIALS 
 
Figure 14. Melanoma cell line heterogeneity in size determined by flow cytometry. 
Cells lines were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM) 
(Thermo Fisher Scientific, USA) supplemented with 10% foetal bovine serum (FBS) 
(Invitrogen, USA). The cultures were maintained at 37 C in a humidified atmosphere 
containing 5% (v/v) CO2 until 80% confluence. Cell lines were passaged every 72 hours 
as per ATCC guidelines. Sub-confluent monolayers were dissociated using 5mM 
Ethylenediaminetetraacetic acid (EDTA) in DMEM. Viability and cell counts of cell 
cultures at every passage were determined using a Vi-CELL XR cell counter (Beckman 
Coulter, USA). Only cell cultures with a viability higher than 80% were used in subsequent 
experiments. 
CellTrackerTM labelling 
For the counting and detection of recovered cells after processing melanoma spiked 
blood samples through the three microfluidic approaches, melanoma cell cultures were 
firstly stained with CellTracker™ Red CMTPX dye (Thermo Fisher Scientific, USA), which 
passes freely through cell membranes into cells, and stains all cells similarly. For the 
CellTracker™ staining, A2058 and SKMEL5 cell cultures were washed twice with PBS 
(137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH of 7.4) after removing the culture media 
followed by incubation in 2 mL of DMEM, containing 2 µL of CellTracker™ dye (1µM) for 
45 min at 37 C in a humidified atmosphere containing 5% (v/v) CO2. After incubation, 
the staining media was removed and two washes with a PBS solution were performed. 
Cells were dissociated using a 5mM EDTA in DMEM solution for 5 minutes and 2 mL of 
10% FBS/DMEM media was added to inhibit dissociation activity. After this, the cells in 
suspension were ready for spiking purposes. Staining of cells was confirmed under an 
inverted fluorescent microscope (Eclipse Ti-E, Nikon®, Japan). 
 
38 4. METHODS AND MATERIALS 
Blood collection 
For all experiments, healthy donors provided signed consent forms, previously approved 
by the Human Research Ethics Committees at ECU (No.11543). The blood was drawn by 
phlebotomists into Vacutainer tubes containing EDTA anticoagulant (Becton-Dickinson, 
USA), after discarding the first 2 mL to avoid epithelial contamination. 
Spiking experiments 
For spiking experiments, in order to mimic the low numbers of CTCs commonly present 
in melanoma patients, 50 x CellTracker-stained melanoma cells derived from either 
A2058 or SKMEL5 cell cultures were manually counted and picked with a pipette under 
the microscope and collected cells were spiked into 8 mL of blood, in triplicate 
experiments. Then, red blood cells were lysed using red blood cell (RBC) lysis buffer (140 
mM NH4Cl, 17 mM Tris, pH 7.65) at a 1:10 vol/vol ratio for 5 min at room temperature 
with continuous gentle mixing. The lysed RBCs were removed after centrifugation at 300 
g for 10 min, and the nucleated cell fraction was washed twice with 20 mL of PBS before 
resuspension into 16 mL (0.5X concentration) of a PBS solution containing 0.5% bovine 
serum albumin (0.5% BSA-PBS) to prevent non-specific adsorption and bubble formation 
during processing. Nucleated cells from blood were processed through the spiral 
microfluidic devices using the three microfluidic approaches: single Slanted (1X Slanted), 
single A5 and double Slanted (2X Slanted). 
Determination of the recovery rate of melanoma cells spiked into blood and isolated 
using the microfluidic devices 
Prior to sample processing, the biochips were washed with ethanol 70% and PBS before 
being primed with PBS/0.5% BSA using a syringe pump (PHD 2000, Harvard Apparatus, 
USA) for around 2 min at a flow rate of 1 mL min−1 for each solution. For isolation of 
melanoma cells, the processed blood samples containing spiked melanoma cells were 
placed in a 20 mL syringe (20 mL Luer-Lok, BD™, USA) and pumped through the device 
using a syringe pump connected to the microchannel device with flexible Tygon® tubing 
(Cole-Parmer, USA) (Figure 15). 
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Figure 15. The workstation setup for melanoma cell or CTC separation. The blood after 
erythrolysis is pumped through the microfluidic device using a syringe pump. 
As recommended in literature11, 199, the flow rate for the input flow of the Slanted chip 
was 1700 μL min−1. For the A5 spiral microfluidic device, a flow rate of 750 μL min−1 was 
used for the sheath inlet and 100 μL min−1 for the blood inlet. 0.5% BSA in PBS buffer was 
used for the sheath inlet in the experiments with the A5 microfluidic device11, 221. 
After processing the sample through 1X Slanted, A5 alone, or 2X Slanted, cells were 
collected from two outlets: one containing the recovered melanoma cells (CTC outlet) and 
the other containing the remaining white blood cells (waste outlet) (Figure 10 and 11). 
For the 2X Slanted approach, the CTC outlet sample, retrieved after processing through 
Slanted the first time, was resuspended in 6 mL of 0.5% BSA/PBS, changed into a syringe 
and pumped directly into the inlet of the Slanted chip using the conditions mentioned 
previously. 
In order to determine the recovery rates, the cellular fraction from the CTC outlet was 
evaluated and counted for each experiment. For this, cells in the CTC fraction were 
separated from the supernatant by centrifugation at 500 g for 5 min. The cell pellet was 
resuspended and transferred to a 12-well plate (Greiner Bio-One, Austria). Using the NIS-
Elements High Content Analysis software, version 4.2 using an inverted fluorescent 
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microscope (Eclipse Ti-E, Nikon®, Japan), cells were identified individually by studying 
both their morphology, and their CellTracker™ staining pattern to allow their correct 
identification as a spiked melanoma cell. A TRITC filter with set excitation and emission 
(Ex/Em) wavelengths of 555/607 nm, was used for red fluorescence identification. 
The recovery rate for each experiment was determined as the number of red-labelled 
cells recovered, divided by the number of spiked cells per experiment. 
Determination of the purity of the enriched fraction 
In order to determine the purity of the recovered fraction, 8 mL of blood from healthy 
donors was run in triplicate through 1X Slanted, A5 and 2X Slanted, counting the WBC 
content with a Neubauer chamber (Hawksley, England), before and after the microfluidic 
isolation. For this, 10µL of a previous dilution of the enriched fraction containing the 
isolated melanoma cells, mixed 1:1 in Trypan Blue (Sigma, USA) was placed in the 
chamber. Total cells present in the four main corner squares were counted. Sample 
concentration was calculated as: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑥 104 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
=  𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿 
For the 2X Slanted approach, WBCs content was determined before, after one round and 
after two rounds. WBCs counts were log10 transformed and depletion rates were 
calculated by comparing the total number of cells after microfluidic processing to the 
initial WBC count. 
Statistical analysis 
To test whether the data was approximately normally distributed, a Shapiro-Wilk’s test 
was used (p>0.05). One-way ANOVA was used to determine if it exists an overall 
difference between the groups analysed and Tukey post-hoc analysis was used to 
determine if the efficiency of the Slanted device to deplete WBCs from the total after 2X 
Slanted enrichment of control samples in particular, was significant. These analyses were 
performed using Microsoft Excel, SPSS Statistical software (version 22.0) and GraphPad 
Prism (version 5.0). Statistical significance was reached with a P <0.05. 
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4.2 Aim 2. To detect CTCs from metastatic melanoma patients enriched 
by the 2X Slanted device, using an optimised immunostaining protocol. 
4.2.1 Experimental design and Methods 
In order to confirm that the 2X Slanted method was able to isolate CTCs from metastatic 
melanoma patients, an optimised multimarker immunostaining assay was developed that 
included melanocyte/melanoma-specific cell surface markers and intracellular markers. 
To ensure that the majority of melanoma CTCs isolated by this device were successfully 
transferred onto glass slides for further immunostaining detection, the cytospin and 
immunostaining processes were optimised prior to processing of blood samples from 
metastatic melanoma patients. The steps followed for the enrichment and detection of 
melanoma CTCs from the blood of metastatic melanoma patients are indicated in the 
schematic below (Figure 16). 
 
Figure 16. Flowchart of CTC enrichment and detection procedures. The processed blood from 
the melanoma patients was run through the 2X Slanted microfluidic device for CTC enrichment 
(A). The CTC output from the microfluidic enrichment was transferred onto slides by 
centrifugation (B) for optimisation of the subsequent immunostaining process (C). Finally, the 
CTCs were identified using an automated fluorescence microscope (D). 
Cell lines and cell culture 
A2058 melanoma cell line was used in the cytospin and staining optimisation processes. 
This melanoma cell line was obtained from the American Type Culture Collection (ATCC, 
USA). 
WBCs isolation from healthy volunteers 
Healthy donors provided signed consent forms, previously approved by the Human 
Research Ethics Committees at ECU (No.11543). The blood was drawn by phlebotomists 
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into Vacutainer tubes containing EDTA anticoagulant (Becton-Dickinson, USA), after 
discarding the first 2 mL to avoid epithelial contamination. 
Then, red blood cells were lysed using red blood cell (RBC) lysis buffer at a 1:10 vol/vol 
ratio for 5 min at room temperature with continuous gentle mixing. The lysed RBCs were 
removed after centrifugation at 300 g for 10 min and the nucleated cell fraction was 
washed twice with 20 mL of PBS before resuspension into 10 mL PBS. Cells were then 
counted using a Vi-CELL XR cell counter (Beckman Coulter, USA) before proceeding with 
the spiking experiments. 
Cytospin optimisation 
In order to confirm that the cells enriched by the 2X Slanted device are entirely 
transferred onto glass slides, the ability of the cytospin to improve recovery of spiked 
cells was tested. For this, and for the following protocol described in section 4.1.1, 50 cells 
from the melanoma cell line A2058 were stained with CellTracker™ and mixed with 
approximately 5x103 WBCs isolated from a healthy control. The cells were pelleted and 
carefully resuspended in a fixing solution of 4% PFA for 10 min at room temperature. 
Thereafter, cells were transferred into a cytofunnel (Shandon™ Single Cytofunnel™ with 
Brown Filter Cards, Thermo Fisher Scientific, USA) precoated with PBS supplemented 
with 0.5% BSA (0.5% BSA /PBS), after washing the tube. Cells were cytospun onto glass 
slides (Cytospin™ 4, Thermo Fisher Scientific, USA; Figure 17) for 5 min, at medium 
acceleration, and different centrifugation speeds: 1000, 1300, 1600, and 2000 rpm to 
identify the optimal centrifugation speed required. Finally, cells were stained with DAPI 
(4',6-diamidino-2-phenylindole) and mounted using ProLong® Gold Antifade Mountant 
with DAPI reagent (Thermo Fisher Scientific, USA). The slides were stored at 4ᵒC until 
analysis by microscopy. Slides were scanned using an automated inverted fluorescent 
microscope (Eclipse Ti-E, Nikon®, Japan; Figure 18), and analysed using the NIS-Elements 
High Content Analysis software, version 4.2. In order to be qualified as a spiked A2058 
cell, the cell needed to have a positive signal for the nuclear DAPI staining and also be 
positive for the CellTracker™ Red dye. The speed that offered the best recovery, was 
tested in triplicate in order to ensure consistency. 
In order to study the recovery rate after microfluidic enrichment followed by the 
cytospin, 50 x A2058 CellTracker™ cells were spiked in triplicate experiments into 8 mL 
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of whole blood from healthy donors. After treating the blood plus melanoma cells with 
lysis buffer and processing the sample through the 2X Slanted device as explained in 
section 4.1.1, the enriched fraction was cytospun using the speed 2000 rpm as this 
provided the highest recoveries without affecting the cell morphology. The number of 
recovered cells in each sample was analysed as described in the previous paragraph. 
 
Figure 17. Cytospin 4® centrifuge used in transferring cells onto slides. 
Optimising the detection of cells processed through the microfluidic device 
Previous studies in our laboratory have described three melanocyte/melanoma-specific 
markers highly expressed in melanoma cell lines. These markers (gp100, Melan-A, s100, 
and MCSP) were previously utilised in a multimarker approach to identify melanoma 
CTCs after immunomagnetic enrichment. In order to test the effectiveness of this 
multimarker immunostaining approach in detecting melanoma cells processed through 
the cytospin, 50 x A2058 cells and approximately 5x103 WBCs isolated from healthy blood 
were mixed, pelleted and carefully resuspended in 4% PFA for 10 min at room 
temperature. Then, cells were cytospun as previously detailed (Cytospin™ 4, Thermo 
Fisher Scientific, USA; Figure 17) for 5 min, at medium acceleration, and 2000 rpm. Cells 
were again fixed with 4% PFA for 10 mins and incubated in a blocking buffer containing 
10% NDS, 3% BSA and 0.2% Triton X-100 (Sigma-Aldrich, USA) in PBS 
(10%NDS/3%BSA/0.2%TX-PBS) for 15 mins. Cells were then incubated in blocking 
buffer for 1 hour at room temperature, containing the multimarker panel: 
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- Three internal markers (referred in this document as ‘MEL-staining’): anti-gp100 
antibody (clone EPR4864, Abcam), anti-Melan-A/MART1 antibody (clone 
EP1422Y, Abcam), and anti-s100 (EP1576Y, Abcam). 
- One surface marker: anti-MCSP antibody conjugated to Alexa Fluor® 647 dye 
(MCSP-647; clone 9.2.27, BD Pharmingen). 
- One leukocyte-specific marker: anti-CD45 antibody conjugated to Phycoerythrin 
(CD45-PE; clone HI30, BD Pharmingen). 
- (See Table 6 for antibody dilution information). 
After incubation, cells were washed three times with 0.2% TX-PBS solution, and 
incubated in blocking buffer with a secondary donkey anti-rabbit IgG antibody 
conjugated to Alexa Fluor® 488 dye (R488; Abcam) for internal marker staining. Finally, 
cells were stained with DAPI and mounted using ProLong® Gold Antifade Mountant with 
DAPI reagent (Thermo Fisher Scientific, USA). Once immunostaining was completed, 
slides were stored at 4ᵒC. 
Slides were scanned using an automated inverted fluorescent microscope (Eclipse Ti-E, 
Nikon®, Japan; Figure 18), and analysed using the NIS-Elements High Content Analysis 
software, version 4.2. 
Internal markers (‘MEL- staining’) were identified using a FITC filter with set excitation 
and emission (Ex/Em) wavelengths of 470/535 nm with an exposure time of 700 ms. The 
signal produced by the cell membrane MCSP-647 dye was identified using a Cy5 filter 
(Ex/Em = 640/720 nm) with an exposure time of 1 s. On the other side, CD45-PE stained 
leukocytes were identified using a TRITC filter (Ex/Em = 555/607 nm) with an exposure 
time of 500 ms. Nuclear staining was identified with a DAPI filter (Ex/Em = 395/460 nm) 
with an exposure time of 200 ms. 
In order to be qualified as A2058 melanoma cell, the cell needed to have positive 
expression for the nuclear DAPI staining and also be positive for either the internal 
melanoma markers (‘MEL-staining’) or MSCP staining, but negative for the CD45 
leukocyte-specific marker. 
Furthermore, the recovery rate of the whole process (Slanted enrichment, cytospin and 
immunostaining) was studied by spiking 50 cells in triplicate experiments into 8 mL of 
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blood from healthy donors. After treating whole blood with RBC lysis buffer and 
processing the sample through the 2X Slanted device as explained in section 4.1.1, the 
enriched fraction was cytospun and stained, as described in the above paragraph. 
Patients and blood collection 
Blood from 10 metastatic melanoma patients, collected prior to clinical treatment with 
targeted inhibitors or immunotherapies, was included in this study (Table 5). Healthy 
volunteers and melanoma patients signed consent forms previously approved by the 
Human Research Ethics Committees at ECU (No.11543) and Sir Charles Gairdner Hospital 
(SCGH, No. 2013-246). The blood was drawn by phlebotomists into one 8 mL Vacutainer 
tube containing EDTA anticoagulant (Becton-Dickinson, USA), after discarding the first 2 
mL to avoid epithelial contamination. 
Table 5. Demographic information of metastatic melanoma patients. 
PATIENTS’ CHARACTERISTICS 
 n % of total 
Total patients enrolled 
 10  
Age at enrolment (years) 
                   Median 68   
                    Range 46 - 78   
Gender 
Male 6 60% 
Female 4 40% 
CTC enrichment using the 2X Slanted enrichment 
An EDTA tube containing 8 mL of blood from a total of 10 metastatic melanoma patients 
and healthy volunteers was used for analysis. Blood samples were processed, within 24 
hours after collection. Whole blood was treated with RBC lysis buffer and washed twice 
with 20 mL of PBS before resuspension in 16 mL (0.5X concentration) of 0.5% BSA/PBS. 
Once the blood had been processed and resuspended into PBS/0.5% BSA, the 16 mL 
nucleated fraction derived from 8 mL of blood was processed through the Slanted using 
a flow rate of 1700 μL min−1. The cellular fraction of the CTC outlet from the first round 
was resuspended in 6 mL of 0.5% BSA/PBS solution and processed again through the 
same Slanted device using an input flow rate of 1700 µL min-1. 
 
46 4. METHODS AND MATERIALS 
CTC detection from the enriched fraction 
The cells recovered in the CTC outlet after processing the sample twice through the 
Slanted microfluidic device, were immediately pelleted and fixed by 10 min incubation 
with 4% PFA. After that, cells were cytospun (Cytospin™ 4, Thermo Fisher Scientific) onto 
glass slides at 2000 rpm for 5 mins at medium acceleration. Cells were again fixed with 
4% PFA for 10 mins and incubated in a blocking buffer (10%NDS/3%BSA/0.2%TX-PBS) 
for 15 mins. Cells were then incubated in blocking buffer for 1 hour at room temperature, 
containing the multimarker panel: 
- Three internal markers (‘MEL-staining’): anti-gp100 antibody (clone EPR4864, 
Abcam), anti-Melan-A/MART1 antibody (clone EP1422Y, Abcam), and anti-s100 
(EP1576Y, Abcam). 
- One surface marker: anti-MCSP antibody conjugated to Alexa Fluor® 647 dye 
(MCSP-647; clone 9.2.27, BD Pharmingen). 
- One leukocyte-specific marker: anti-CD45 antibody conjugated to Phycoerythrin 
(CD45-PE; clone HI30, BD Pharmingen). 
- (See Table 6 for antibody dilution information). 
After incubation, cells were washed three times with 0.2% TX-PBS solution, and 
incubated in blocking buffer with a secondary donkey anti-rabbit IgG antibody 
conjugated to Alexa Fluor® 488 dye (R488; Abcam) for the internal markers staining. 
Finally, cells were stained with DAPI and mounted using ProLong® Gold Antifade 
Mountant with DAPI reagent (Thermo Fisher Scientific, USA). Once immunostaining was 
completed, slides were stored at 4ᵒC. 
Slides were scanned using an automated inverted fluorescent microscope (Eclipse Ti-E, 
Nikon®, Japan; Figure 18), and analysed using the NIS-Elements High Content Analysis 
software, version 4.2 using the same fluorescent filters and exposure times as indicated 
above. 
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Figure 18. Eclipse Ti-E, Nikon® fluorescent automated microscope and software used in CTC 
quantification and analysis. 
Additionally, cell sizes were also measured with this software. Background subtraction 
parameters for each marker derived from the immunostaining of A2058 melanoma cells 
spiked into WBC fractions, were stringently applied to all stained slides of CTC samples 
from patients. For this, the fluorescent intensity cut-offs applied in the analysis were: 
2000 LUTs for FITC filter, 300 LUTs for Cy5 filter, 2000 LUTs for TRITC filter, and 1500 
LUTs for DAPI filter. 
In order to be identified as a CTC, the cell needed to have positive expression for nuclear 
DAPI staining and also be positive for either the internal melanoma markers (‘MEL-
staining’) or MSCP staining, but negative for the CD45 leukocyte-specific marker. 
Table 6. Antibody information (Aim 2). 
Antibody 
Antigen 
Location 
Vendor Dilution used Notes 
gp100 Cytosol 
Abcam 
Clone EPR4864 
1/50 
Included in the 
Multimarker Panel 
MART1 Cytosol 
Abcam 
Clone EP1422Y 
1/50 
Included in the 
Multimarker Panel 
S-100 Cytosol 
Abcam 
Clone EP1576Y 
1/500 
Included in the 
Multimarker Panel 
MCSP-
AF647 
Membrane 
BD 
Pharmingen™ 
Clone 9.2.27 
1/200 
Included in the 
Multimarker Panel 
CD45-PE Membrane 
BD 
Pharmingen™ 
Clone HI30 
1/20 
Leukocyte-specific 
antibody 
Donkey 
anti-rabbit-
R488 
n/a 
Abcam 
ab150065 
1/500 
Anti-rabbit 
Secondary Polyclonal 
Ab 
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Determination of the purity of the enriched fraction 
In order to determine the purity of the recovered fraction after using the 2X Slanted 
approach, WBC content was determined in five patients, before and after one round of 
enrichment by counting cells in a Neubauer chamber (Hawksley, England). For this, 10µL 
of a previous dilution of the enriched fraction containing the isolated melanoma cells 
were mixed 1:1 in Trypan Blue (Sigma, USA) was placed in the chamber. Total cells 
present in the four main corner squares were counted. Sample concentration was 
calculated as: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑥 104 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠
=  𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿 
After the second round of enrichment, WBC count was performed on the immunostained 
slides using an inverted fluorescent microscope equipped with the NIS-Elements High 
Content Analysis software, version 4.2. This software allows identification and 
quantification of single DAPI stained circular profiles with a set maximum area of 350 
µm2. WBCs counts were log10 transformed and depletion rates were calculated by 
comparing the total number of cells after microfluidic processing to the initial WBC count. 
Statistical analysis 
To test whether the data was approximately normally distributed, a Shapiro-Wilk’s test 
(p>0.05) was used. One-way ANOVA was used to determine if it exists an overall 
difference between the groups analysed and Tukey post-hoc analysis was used to 
determine if the efficiency of the Slanted device to deplete WBCs from the total after 2X 
Slanted enrichment of melanoma patient samples in particular, was significant. These 
analyses were performed using Microsoft Excel, SPSS Statistical software (version 22.0) 
and GraphPad Prism (version 5.0). Statistical significance was reached with a P <0.05. 
4.3 Aim 3. To test additional cellular markers that can be used in 
immunostaining assays for optimisation of detection and phenotypic 
characterisation of heterogeneous melanoma CTCs. 
4.3.1 Experimental design and Methods 
Figure 19 shows the main steps followed in order to determine melanoma markers are 
expressed in melanoma cells and potentially expressed by CTCs from melanoma patients. 
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Figure 19. Overview of the process for all staining experiments. Melanoma cells were either 
seeded on coverslips or mixed with WBCs and cytospun onto glass slides (A). The cells were 
stained with the chosen biomarkers by immunocytochemistry (B). Finally, automated 
fluorescence scanning allowed the analysis of the immunostained cells with different markers 
(C). 
Immunocytochemical staining of additional melanoma cell markers most commonly 
expressed in melanoma cell line cells for optimal melanoma cell/CTC detection 
The optimisation of the immunostaining protocol by the addition of supplementary 
melanocyte/melanoma markers to the staining protocol for detection of an increased 
number of melanoma cells was completed using cells derived from melanoma cell lines. 
The expression of three additional markers (Vimentin, RANK and ABCB5) was assessed 
in A2058, WM164 and SKMEL5 melanoma cell lines in order to identify additional 
markers expressed in all or in the majority of the melanoma cells derived from cell lines, 
so as to best identify additional markers that can be used to stain and identify 
heterogeneous melanoma cells. 
Firstly, the optimal concentration of the antibodies was assessed by determining the 
concentration that provided optimal staining with minimal background staining using 
A2058 cells cytospun and stained on cover slips. The optimal concentration was then 
used to stain another two cell lines to confirm the expression pattern of the marker in 
multiple melanoma cell lines. 
Cell lines and cell culture 
SKMEL5, A2058 and WM164 melanoma cell lines were used. The melanoma cell line 
WM164 was kindly provided by Professor Meenhard Herlyn from The Wistar Institute 
(Philadelphia, USA) and A2058 and SKMEL5 melanoma cell lines were obtained from the 
American Type Culture Collection (ATCC, USA) (Figure 20). 
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Figure 20. Microscopic bright field caption of A2058 cells (A), WM164 cells (B), and SKMEL5 
cells (C) in culture. All images taken at 10x magnification. Scale Bar: 200 µm. 
Cells were seeded on sterile square glass cover slips in 12-well cell culture plates (Greiner 
Bio-One, Austria) and incubated for 24 hours in high-glucose DMEM (Invitrogen, USA) 
supplemented with 10% FBS (Invitrogen, USA) and maintained at 37 C in a humidified 
atmosphere containing 5% (v/v) CO2. 
WBCs isolation from healthy volunteers 
Healthy donors provided signed consent forms, previously approved by the Human 
Research Ethics Committees at ECU (No.11543). The blood was drawn by phlebotomists 
into Vacutainer tubes containing EDTA anticoagulant (Becton-Dickinson, USA), after 
discarding the first 2 mL to avoid epithelial contamination. 
Red blood cells were lysed using red blood cell (RBC) lysis buffer at a 1:10 vol/vol ratio 
for 5 min at room temperature with continuous gentle mixing. The lysed RBCs were 
removed after centrifugation at 300 g for 10 min and the nucleated cell fraction was 
washed twice with 20 mL of PBS before resuspension into 10 mL PBS. Cells were then 
counted using a Vi-CELL XR cell counter (Beckman Coulter, USA) before proceeding with 
the spiking experiments. 
Immunofluorescent staining of the melanoma cell lines 
Attached cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 10 
minutes at room temperature and then washed 3 times with PBS. Cell surface and 
intracellular markers were stained using different immunostaining protocols, as 
described below. 
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RANK cell surface marker was stained by incubating the cells with anti-RANK mouse 
antibody (clone 80704, R&D Systems) diluted in 3% BSA/PBS for one hour at room 
temperature. Antibody dilutions of 1/20, 1/50, and 1/100 were tested. 
Subsequently, melanoma cells were washed 3 times with PBS and incubated with a 
secondary donkey anti-mouse IgG polyclonal antibody conjugated to Alexa Fluor® 488 
dye (M488; Abcam) diluted 1/500 in 3%BSA/PBS and kept for 15 min at room 
temperature in the dark. 
Intracellular markers were stained after permeabilising the cells with 0.2% TX-PBS for 
10 min subsequent to fixing of the cells with 4% PFA solution for 10 min. Cells were then 
incubated with primary antibodies diluted in 3% BSA/0.2%TX-PBS solution for one hour 
at room temperature: 
- Anti-Vimentin antibody conjugated to Alexa Fluor® 647 dye (VIM-647; clone V9, 
Abcam) was tested using dilutions of 1/1000, 1/2000, and 1/5000. 
- Anti-ABCB5 mouse antibody (clone 5H3C6, Abcam) was tested using 1/20, 1/50, 
and 1/100 dilutions. 
For the ABCB5 marker, melanoma cells were washed 3 times with 0.2%TX-PBS and 
incubated with a donkey anti-mouse IgG polyclonal antibody conjugated to Alexa Fluor® 
488 dye (M488; Abcam) diluted 1/500 in 3% BSA/0.2%TX-PBS and kept for 15 min at 
room temperature in the dark (See Table 7). 
Lastly, after the melanoma cells were stained for either cell surface or intracellular 
markers and secondary antibodies, cells were mounted with Prolong® Gold antifade 
reagent with DAPI mounting media (Thermo Fisher Scientific, USA) for nuclear staining 
and preservation of the cells. The slides were kept at 4 C until their analysis was 
performed. 
Slides stained with RANK and ABCB5 were scanned using a fluorescence microscope 
(BX51, OLYMPUS, Japan) with a FITC and DAPI filter. Negative controls that involve 
incubating the sample with secondary antibodies only were performed for each marker 
and in each cell line in order to detect the background level of expression. The expression 
analysis was performed using the DPController software, version 3.3.1.292 and 
background subtraction was performed for each marker and cell line by adjusting the 
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intensities and exposures as per matched negative controls. On the other hand, slides 
stained with Vimentin were scanned using an automated inverted fluorescent 
microscope (Eclipse Ti-E, Nikon®, Japan; Figure 18), and analysed. 
Negative controls that involve incubating the sample with an isotype matched antibody 
labelled with Alexa Fluor® 647 dye at the same concentration as the Vimentin antibody 
were performed for each cell line in order to detect any background non-specific signal. 
Background subtraction was performed for each cell line and marker Using the NIS-
Elements High Content Analysis software, version 4.2 using the Cy5 filter to identify the 
marker staining and the DAPI filter for nuclear recognition, background subtraction 
parameters were adjusted for each marker by altering the fluorescent intensity cut-offs 
(LUTs) as per matched negative controls. After background subtraction, signal for each 
fluorescent dye was also adjusted to enhance the staining for each marker. 
Table 7. Antibody information (Aim 3). 
Antibody 
Antigen 
Location 
Vendor 
Dilutions 
tested 
Dilution 
used 
Notes 
RANK Membrane 
R&D Systems 
Clone 80704 
1/20 
1/50 
1/100 
1/20 Additional Ab tested 
Vimentin-AF647 Cytosol 
Abcam  
Clone V9 
1/1000 
1/2000 
1/5000 
1/1000 Additional Ab tested 
ABCB5 
Internal 
Membrane 
Abcam 
Clone 5H3C6 
1/20 
1/50 
1/100 
1/20 Additional Ab tested 
ABCB5 
External 
Membrane 
1D12 
n/a (donated) 
1/550 
1/275 
1/100 
1/275 Tested for TSA 
MCSP Membrane 
BD Pharmingen™ 
554275 
n/a 1/500 Positive control for TSA 
CD45-PE Membrane 
BD Pharmingen™ 
Clone HI30 
n/a 1/20 
Leukocyte-specific 
antibody 
Donkey anti-
mouse-AF488 
n/a 
Abcam 
Ab150109 
n/a 1/500 
Secondary Polyclonal 
Ab 
TSA: Tyramide Signal Amplification 
Optimised immunofluorescent staining of A2058 melanoma cells spiked into WBCs 
The specificity of the selected markers was next assessed by determining their expression 
patterns when A2058 melanoma cell line cells were spiked into WBCs isolated from the 
blood of healthy donors. This was required to ensure that the WBCs did not express the 
melanoma markers and to ensure that the staining remained optimal when melanoma 
cells were spiked into WBCs. 
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For this, melanoma cells of the A2058 cell line were spiked into WBCs from healthy 
volunteers. Spiking and whole blood RBCs lysis were performed as previously described 
in section 4.1.1. Approximately 5x103 A2058 melanoma cells and 105 WBCs were mixed, 
pelleted and fixed by resuspending them in 2% PFA for 10 min. Then, cells were 
transferred onto glass slides using the Cytospin 4® centrifuge (Thermo Fisher Scientific, 
USA; Figure 17) for 5 min, at 2000 rpm with medium acceleration. Attached cells were 
then fixed again with 4% PFA for 10 min and washed twice with PBS in a coupling jar. 
After the cells were cytospun and fixed onto glass slides, cells were blocked with a 
blocking buffer containing 10% normal donkey serum (NDS), 3% bovine serum albumin 
(BSA) diluted in PBS or in 0.2% TX-PBS for internal markers staining. Subsequently, cells 
were incubated with different antibodies at their optimal dilutions (Vimentin: 1/1000; 
RANK: 1/20 and ABCB5: 1/20), in blocking buffer for one hour at room temperature. 
Then, cells were washed 3 times with PBS or 0.2% TX-PBS (for intracellular markers) and 
incubated for 15 min at room temperature in the dark with a donkey anti-mouse IgG 
polyclonal antibody conjugated to Alexa Fluor® 488 dye (M488; Abcam) diluted 1/500 in 
blocking buffer. In addition, a leucocyte marker, anti-CD45 antibody conjugated to 
Phycoerythrin (PE) (CD45-PE; clone HI30, BD Pharmingen) was used to specifically stain 
the leucocytes at 1/20 dilution. After washing again 3 times with PBS or 0.2% TX-PBS (for 
intracellular markers), cells were mounted with Prolong® Gold antifade reagent with 
DAPI mounting media (Thermo Fisher Scientific, USA) for nuclear staining and 
preservation of the cells. 
The slides were kept at 4 C until their analysis was performed. Slides were scanned using 
an automated inverted fluorescent microscope (Eclipse Ti-E, Nikon®, Japan). Marker 
expression patterns were analysed using the NIS-Elements High Content Analysis 
software, version 4.2. 
RANK and ABCB5 markers were identified using a FITC filter with set excitation and 
emission (Ex/Em) wavelengths of 470/535 nm with an exposure time of 700 ms. The 
signal produced by VIM-647 expression was identified using a Cy5 filter (Ex/Em = 
640/720 nm) with an exposure time of 1 s. On the other side, CD45-PE stained leukocytes 
were identified using a TRITC filter (Ex/Em = 555/607 nm) with an exposure time of 500 
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ms. Nuclear staining was identified with a DAPI filter (Ex/Em = 395/460 nm) with an 
exposure time of 200 ms. 
In order to be counted as appropriately stained, the cell needed to have positive 
expression for the nuclear DAPI staining and also be positive for the melanoma marker 
tested (Vimentin, RANK or ABCB5), but negative for the CD45 leukocyte-specific marker. 
Background subtraction parameters were adjusted for each marker by altering the 
fluorescent intensity cut-offs (LUTs). After background subtraction, signal for each 
fluorescent dye was also adjusted to enhance the staining for each marker. 
Tyramide Signal Amplification (TSA) 
In order to further enhance signal of markers that were weakly/intermittently expressed 
in melanoma cell lines, such as ABCB5, a tyramide signal amplification (TSA) 
methodology was tested (Figure 21). 
 
Figure 21. Tyramide Signal Amplification principle. 
Since ABCB5 marker is commonly expressed on CTCs170, and the ABCB5 staining protocol 
trialled above produced weak and suboptimal staining, we utilised a Tyramide Siganl 
Amplification (TSA) protocol to amplify the immunohistochemical staining signal of 
ABCB5. To interrogate, for the first time, the ability of this method to increase the signal 
of ABCB5 staining, an anti-ABCB5 antibody that binds to an epitope of the ABCB5 protein 
that is located in the external membrane of the cell was used, as this was identified 
previously as being commonly expressed on melanoma CTCs170. 
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For this, A2058 cells were seeded on sterile square glass cover slips in 12-well cell culture 
plates (Greiner Bio-One, Austria) and incubated for 24 hours in DMEM (Invitrogen, USA) 
supplemented with 10% foetal bovine serum (FBS) (Invitrogen, USA) and maintained at 
37 C in a humidified atmosphere containing 5% (v/v) CO2. 
Attached cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 10 
minutes at room temperature and then washed 3 times with PBS. Cells were then blocked 
with a TBS blocking buffer (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5) supplemented with 3% 
BSA at room temperature for 15 min. Anti-ABCB5 mouse antibody (Clone 1D12) was then 
incubated for 1 hour at room temperature, diluted 1/275 in blocking buffer and the slides 
were washed three times in TBS-Tween washing buffer (0.1 M Tris-HCl, 0.15 M NaCl, pH 
7.5, 0.05% Tween-20) for 5 min each under continuous shaking were performed. 
Incubation with anti-mouse antibody labelled with horseradish peroxidase (HRP; Perkin 
Elmer, USA) diluted 1/1000 in blocking buffer was performed for 30 min at room 
temperature. After washing again with washing buffer, the sample was incubated in TSA 
Plus Working Solution (Fluorescein; Perkin Elmer, USA) for 5 min. The sample was once 
again washed three times for 5 min each in continuous shaking before mounting with 
Prolong® Gold antifade reagent with DAPI mounting media (Thermo Fisher Scientific, 
USA) for nuclear staining and preservation of the cells. For this experiment, anti-MCSP 
antibody diluted 1/500 (BD Pharmingen) was included as a positive control since MCSP 
is highly expressed in the A2058 melanoma cell line4. Additionally, a negative control that 
involved incubating the sample with the secondary antibody only was performed in order 
to detect the background level of expression. 
In order to test the specificity of the staining, A2058 melanoma cells were spiked into 
WBCs from healthy donors as detailed in section 4.1.1, processed and stained. For this, 
cells cytospun onto slides were fixed for 10 min with 4% PFA and washed three times 
with PBS. In order to quench the endogenous peroxidase activity of the blood cells, an 
incubation in 0.3% H2O2 in PBS for 20 min was performed. After washing again with PBS, 
cells were incubated for 1 hour at room temperature with anti-ABCB5 mouse antibody 
(Clone 1D12), diluted 1/275 in blocking buffer and washed three times in TBS-Tween 
washing buffer (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5, 0.05% Tween-20) for 5 min each 
under continuous shaking. Incubation with anti-mouse antibody labelled with 
horseradish peroxidase (HRP; Perkin Elmer, USA) diluted 1/1000 in blocking buffer was 
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performed for 30 min at room temperature. After washing again with washing buffer, the 
sample was incubated in TSA Plus Working Solution (Fluorescein; Perkin Elmer, USA) for 
5 min. The sample was once again washed three times for 5 min each in continuous 
shaking before incubating the sample with a leucocyte marker, anti-CD45 antibody 
conjugated to Phycoerythrin (PE) (CD45-PE; clone HI30, BD Pharmingen at 1/20 
dilution) to specifically stain the leucocytes. After washing again with washing buffer, 
cells were mounted with Prolong® Gold antifade reagent with DAPI mounting media 
(Thermo Fisher Scientific, USA) for nuclear staining and preservation of the cells. 
Additionally, anti-MCSP antibody diluted 1/500 (BD Pharmingen) was included as a 
positive control. Additionally, a negative control of mouse IgG1 isotype antibody (clone 
MOPC-21; Abcam, USA) alone was used to detect the any background non-specific signal. 
Slides were kept at 4 C until their analysis was performed. Slides were scanned using an 
automated inverted fluorescent microscope (Eclipse Ti-E, Nikon®, Japan), and analysed 
using the NIS-Elements High Content Analysis software, version 4.2 to measure the 
marker expression patterns. This software was used to scan across the slide using a FITC 
filter with set excitation and emission (Ex/Em) wavelengths of 470/535 nm with an 
exposure time of 100 ms or 700 ms to identify ABCB5 and MCSP expression; TRITC filter 
(Ex/Em = 555/607 nm) with an exposure time of 500 ms was used for the recognition of 
CD45-PE stained leukocytes; and nuclear staining was identified with a DAPI filter 
(Ex/Em = 395/460 nm) with an exposure time of 200 ms. In order to subtract the 
background expression, fluorescent intensity cut-offs were applied and adjusted for each 
marker, matching the negative controls values. 
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5. RESULTS 
5.1 Aim 1. To measure the efficiency of three spiral microfluidic 
approaches to isolate differently sized melanoma cell lines spiked into 
healthy control blood. 
5.1.1 Recovery rates using microfluidic devices 
To assess the capacity of the spiral microfluidic devices to enrich and recover melanoma 
cells, 50 x CellTracker labelled cells from two cell lines, with different cell sizes (A2058 
and SKMEL5), were spiked into 8 mL of blood donated by healthy volunteers and 
processed through 1X Slanted, A5 and 2X Slanted spiral microfluidic approaches. 
As observed in Figure 22, the lowest recovery rate for both cell lines was found after 
processing the sample through the A5 chip, with an average of 33%. Conversely, the use 
of 1X Slanted provided the highest average recovery rate of more than 70% regardless of 
the cell size. The 2X Slanted enrichment caused an average recovery rate of 73.3% when 
spiking the small A2058 cells, and 56% when the larger SKMEL5 cells were spiked. 
Interestingly, the average recovery rates for SKMEL5 cells were lower than for A2058 
cells regardless of the enrichment approach used. 
 
Figure 22. Recovery rates from the three enrichment procedures using 50 x spiked cells from 
two different cell lines with different cell sizes. Experiments were performed in triplicate using 
blood samples from healthy donors (n=3). 
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5.1.2 Purity analysis 
To evaluate the purity of the enriched fractions, WBCs were counted in the sample prior 
to and after processing through the microfluidic chips. 
Results showed that by running the sample through the 1X Slanted device, a 2 log 
reduction in WBCs was achieved (mean: 9.0 x 104; range: 0.56-1.45 x 105) relative to the 
initial WBC count (mean: 1.2 x 107; range: 0.8-1.62 x 107). Similarly, using the A5 device 
a 2 log reduction was achieved (mean: 4.3 x 105; range: 2.15-5.45 x 105) relative to the 
initial WBC count (mean: 1.6 x 107; range: 1.54-1.80 x 107) (Figure 23). 
The need to achieve a higher purity in the enriched fraction, led us to add a second round 
of enrichment through the Slanted chip, referred to as double Slanted enrichment (2X 
Slanted). This approach offered the highest purity achieving a 3 log reduction in WBC 
counts (mean: 1.8 x 104; range: 6750-38250) relative to the initial amount of WBCs 
(mean: 1.4 x 107; range: 1.2-1.7 x 107) (Figure 23). Two rounds of enrichment through 
the Slanted, showed a significant depletion in WBCs in the enriched fraction (P<0.0001). 
In addition, these results show that after 1X Slanted, the recovery of A2058 melanoma 
cells drops to 86% and the WBC background results in 73.4% from the total. Although 
after 2X Slanted, the recovery of A2058 melanoma cells drops to 73%, the WBC 
background represents only 14.7% from the total, confirming the ability of this chip to 
reduce the WBC background without drastically impacting the recovery rates. Overall, 
the 2X Slanted protocol provided the best balance between recovery and WBC 
background reduction needed to implement downstream applications. 
 
Figure 23. WBC counts in the blood of healthy donors (n=3) before and after one or two rounds 
of enrichment. Each experiment was performed in triplicate using blood samples from healthy 
donors (n=3). 2X Slanted enrichment showed significant depletion in the WBC count (p<0.0001). 
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5.2 Aim 2. To detect CTCs from metastatic melanoma patients enriched 
by the 2X Slanted device, using an optimised immunostaining protocol. 
5.2.1 Cytospin optimisation 
In order to confirm that the majority of melanoma cells are transferred onto glass slides 
using the cytospin centrifuge, 50 x A2058 cells stained with CellTracker™ and WBCs from 
healthy volunteers were cytospun at four different speeds. The majority of spiked cells 
were recovered when 2,000 rpm was used. To ensure consistency, this speed was tested 
in triplicate, and an average recovery rate of 94% was achieved (Figure 24). 
 
Figure 24. Recovery rates of 50 x A2058 cells labelled with CellTracker after centrifuging them at 
different speeds with the Cytospin centrifuge. 2000 rpm speed was tested in triplicate. 
Finally, 50 x A2058 cells stained with Celltracker™, were spiked in triplicate into 8 mL of 
blood from healthy volunteers, RBCs were lysed, and the sample was processed twice 
through the 2X Slanted device prior to cytospinning the sample onto glass slides using a 
speed of 2000 rpm. Results showed an average overall (microfluidics plus cytospin) 
recovery rate of 58% spiked cells (Figure 25). 
5.2.2 Staining optimisation 
To ensure that the multimarker immunoassay, previously described in section 4.2.1, is 
effective in detecting melanoma cells that have been transferred onto glass slides using 
the cytospin centrifuge, 50 x A2058 cells were spiked in approximately 104 WBCs and 
cytospun at 2,000 rpm and stained with the multimarker panel in triplicate. Markers 
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included MCSP, a melanoma cell surface specific marker, together with a mixture of 
internal melanocytic markers, gp100 (glycoprotein 100), Melan-A, and s100 (‘MEL-
staining’) in order to ensure detection of the majority of melanoma cells. Results showed 
an average recovery rate of 92% (Figure 25). 
When the same experiment, using 50 x A2058 cells spiked into healthy blood was 
performed by conducting the entire process (2X Slanted processing, cytospin and 
multimarker immunostaining), the overall average recovery rate was 52% (ranging from 
48 to 56%; Figure 25). Thus, the entire process of 2X Slanted resulted in a decrease in the 
number of recovered melanoma cells. 
 
Figure 25. Recovery rates of 50 A2058 cells A) Stained with CellTracker® and directly 
transferred onto glass slides using Cytospin, B) Stained with Cell Tracker®, spiked into blood, 
processed through the 2X Slanted device and transferred onto glass slides using the Cytospin, C) 
Directly transferred onto glass slides using Cytospin and stained using the melanoma associated 
markers, and D) Spiked into blood, processed using the 2X Slanted device and transferred onto 
glass slides using the Cytospin prior to staining with the melanoma associated markers. 
Interestingly, although the A2058 spiked cells are thought to be identical as they arise 
from a cell line, they showed different patterns of staining (Figure 26) in multiple 
experiments, with some cells being stained for only the internal set of markers (Figure 
26, CELL 1), other cells for only the MCSP surface marker (Figure 26, CELL 2) and some 
cells were stained for both internal and surface markers (Figure 26, CELL 3). 
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Figure 26. Microscopic images showing the differential expression of intracellular and cell 
surface markers in A2058 cells stained after 2X Slanted microfluidic enrichment. The 
immunostaining used to detect melanoma cells uses a combination of intracellular markers –
‘MEL staining’- (gp100, MLANA and s100; AF488 -FITC- Shown here as green), and a surface 
marker (MCSP; AF467 -Cy5- Shown here as purple). DAPI (UV- Shown here as blue) was used as 
a nuclear stain and CD45 (PE-TRITC- Shown here as red) as a leukocyte-specific marker. 
Results show that the majority of the detected cells were positive for internal and 
external markers (55%), more than a third expressed only the MCSP surface marker 
(39%) and only 6% of the detected cells were positive for the internal markers only. This 
results showed that combining numerous markers in the detection of these 
heterogeneous cells increases our ability to detect them. The use of different emission 
wavelengths to identify the different markers, with the internal markers (FITC) and cell 
surface markers (Alexa Fluor® 647) allowed the detection of this marker diversity. 
5.2.3 CTCs isolated from the blood of melanoma patients 
The above results showed the ability of the multimarker panel used in immunostaining 
to successfully detect melanoma cells that have been enriched with the 2X Slanted 
microfluidic device. In order to validate this enrichment (Aim 1) and detection procedure, 
blood samples from 10 metastatic melanoma patients were analysed. A total of 8 mL of 
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blood was treated with lysis buffer in order to deplete red blood cells. Then, the sample 
was processed through the Slanted microfluidic device using the 2X Slanted approach, 
the recovered cell fraction was cytospun and then immunostained with the multimarker 
panel described above. 
True CTCs were identified by positive staining for intracellular markers (‘MEL staining’) 
or cell membrane MCSP as well as negative staining for the leukocyte-specific marker 
CD45 (Figure 27). 
Using these enrichment and detection procedures, CTCs were effectively detected in the 
blood of 4 patients (40%). Two patients had 1 CTC (CELL 1 and 2), one patient had 3 CTCs 
(CELL 3-5) and the other was found with 4 CTCs (CELL 6-9) in 8 mL of blood (Figure 27). 
Interestingly, all detected CTCs were positive only for the combination of intracellular 
markers (‘MEL staining’ -gp100, Melan-A, and s100-) and no CTC expressing the cell 
membrane marker MCSP was found in any of these patients. Size analyses confirmed that 
CTCs were larger than the majority of white blood cells, exhibiting an average cell size of 
19 µm (range: 13–24 µm), while WBC cell sizes were on average 10 µm (range: 8–12 µm). 
All detected CTCs were presented as single cells and no clusters of CTC cells were 
detected (Figure 27). 
In addition, blood samples from three healthy controls were processed using the same 
protocol. The immunostaining of these samples showed that no CTCs were detected in 
the healthy control blood samples analysed. 
5.2.4 Purity analysis of metastatic melanoma patients samples 
To assess the purity of the enriched fractions when isolating cells from patients, WBC 
counts were completed before and after processing 8 mL of blood from five metastatic 
melanoma patients once and twice through the Slanted microfluidic device. As illustrated 
in Figure 28, a 2-3 log reduction in WBCs compared to the initial WBC count of 3.5 x 107 
(range: 2.36 x 107 - 4.94 x 107) was achieved, after the first round of Slanted, 7.7 x 105 
WBCs (range: 2.45 x 105 - 4.65 x 105) and after 2X Slanted, 8.7 x 104 WBCs (range: 46,532 
– 123,203). A second round of enrichment significantly depleted the WBCs (p<0.0001) in 
patient samples even though the initial amount of WBCs was higher in patients than in 
healthy controls. 
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Figure 27. Expression pattern of intracellular and cell surface markers in CTCs isolated from 
metastatic melanoma patients. The immunostaining used a combination of intracellular markers 
-‘MEL staining’- (gp100, MLANA and s100; AF488 -FITC- Shown here as green), and a surface 
marker (MCSP; AF647 -Cy5- Shown here as purple). DAPI (UV- Shown here as blue) was used as 
a nuclear stain and CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. 
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Figure 28. WBCs counts in five patients prior to and after 1 and 2 rounds through the Slanted 
microfluidic device. A second round of enrichment showed significant depletion of WBCs 
(p<0.0001). 
5.3 Aim 3. To test additional cellular markers that can be used in 
immunostaining assays for optimisation of detection and phenotypic 
characterisation of heterogeneous melanoma CTCs. 
5.3.1 Optimisation of immunostaining assays 
The low number of CTCs identified in patients with active metastatic disease, revealed 
the urgent need to test additional markers that can be used for detection of CTCs in 
samples processed through the Slanted microfluidic device. This is supported by previous 
observations that melanoma CTCs are heterogeneous and most commonly express 
cancer stem cells markers (ABCB5 and RANK) in addition to melanoma specific markers 
(gp100, Melan-A s100, and MCSP)4, 170, 174. Thus, it is possible that these stem cell-like 
melanoma CTCs were not detected in the patient samples isolated above, because these 
stem-like CTCs may not express the melanocytic markers included in our panel. 
Therefore, in this project, we established staining protocols for an additional 3 markers 
associated with cancer stem cell features: Vimentin213, RANK215, and ABCB5222. These 
markers have been detected previously in melanoma CTCs170 and therefore their 
inclusion in this study could potentially improve melanoma CTC detection rates. 
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Firstly, the optimal dilutions of the antibodies used for their detection was determined 
by studying the immunocytochemical staining at different dilutions. Secondly, their 
expression in three melanoma cell lines (A2058, WM164, and SKMEL5) was analysed. 
Overall, the optimal immunostaining protocol for detection of expression of these 
markers in melanoma cells and the optimal antibody dilution was determined (see Table 
7). Results from these experiments will inform future studies of the expression of these 
stem-like markers in CTCs from melanoma patients. 
Each antibody was tested using three different dilutions as per the manufacturer´s 
recommendations. The optimal concentration of each antibody was assessed by 
determining the concentration that provided optimal immunocytochemical staining in 
melanoma cells whilst showing minimal background/ non-specific staining. 
 
Figure 29. Antibody dilution optimisation. A2058 cells stained with different dilutions of 
Vimentin (AF647 -Cy5- Shown here as purple), RANK and ABCB5 (AF488 -FITC- Shown here as 
green). DAPI for nuclear recognition (UV- Shown here as blue). Negative controls were assessed 
for each marker (M488 for ABCB5 and RANK, and -647 ISO for Vimentin). Images at 40x 
magnification. Scale bar denotes 100 µm. 
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As shown in Figure 29, using an optimal concentration of 1/1000, anti-vimentin antibody 
stained the highest number of melanoma cells. A dilution of 1/20 for the anti-RANK 
antibody stained cells with minimal non-specific staining. Similarly, a dilution of 1/20 for 
the anti-ABCB5 antibody showed weak staining in a large number of cells. 
5.3.2 Analysis of stem cell marker expression in melanoma cell lines 
The optimal dilutions determined above for each marker were used to stain two 
additional melanoma cell lines: WM164, and SKMEL5 and the results were compared to 
those received for A2058 stained cells. 
Table 8. Expression analysis of Vimentin, RANK and ABCB5 markers across three 
melanoma cell lines. 
 Proportion of cells with positive staining (%) 
 
` 
Marker A2058 WM164 SKMEL5 Level of expression* 
Vimentin 
0-20 40-60 0-20  High 
20-40 20-40 20-40  Moderate 
20-40 0-20 20-40  Low 
RANK 
0 0 0  *Exemplified in Figure 29 
0-20 0-20 0   
20-40 0-20 20-40   
ABCB5 
0 0 0   
0 0 0   
40-60 0-20 0-20   
 
 
Figure 30. Differential staining to exemplify the level of expression of Vimentin, RANK, and 
ABCB5 across three melanoma cell lines. 1. Low level of expression. 2. Moderate level of 
expression. 3. High level of expression. Scale bar denotes 40 µm. 
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The expression analysis revealed high Vimentin expression, predominantly by WM164 
cells (60%). However, some A2058 and SKMEL5 cells also had also high Vimentin staining 
intensities. In addition, a greater proportion of cells expressed moderate Vimentin 
staining across all cell lines, with SKMEL5 and A2058 being the cell lines with more cells 
presenting low staining intensities (Table 8; Figure 31). 
RANK was mainly expressed by the A2058 cell line at moderate to low levels of 
expression. WM164 also expressed this marker in less than half of the cells at moderate 
to low levels of expression. On the other hand, SKMEL5 showed low levels of RANK 
expression in approximately half of the cells (Table 8; Figure 31). 
ABCB5 was the marker with the lowest expression across all cell lines. Low levels of 
expression were mainly observed in the majority of the A2058 cells. The other two cell 
lines, WM164 and SKMEL5 expressed this marker at low levels in only some cells and no 
positive staining for ABCB5 was present in most of the cells (Table 8; Figure 31). 
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Figure 31. Expression pattern of the three additional markers across three melanoma cell lines 
(A2058, WM164 and SKMEL5). Intracellular markers Vimentin (AF647 -Cy5- Shown here as 
purple) and ABCB5 (AF488 -FITC- Shown here as green), and cell surface marker RANK (AF488 -
FITC- Shown here as green). DAPI was used as a nuclear stain (UV- Shown here as blue). Negative 
controls were assessed for each marker in each cell line (647 ISO for Vimentin, and M488 for 
ABCB5 and RANK). Images at 40x magnification. Scale bar denotes 100 µm. 
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5.3.3 Analysis of the specificity 
To determine the specificity of the markers in staining melanoma cells and not WBCs, 
A2058 cells were spiked into WBCs and transferred onto glass slides using the Cytospin 
then stained for each marker. In addition, negative control experiments were performed 
for each marker. 
Vimentin 
Vimentin showed different patterns of staining in spiked cells (Figure 32). Around 60% 
of cells had low expression of this marker and were slightly stained (i.e. Figure 32, CELL 
1), whereas 30% of cells expressed higher amounts of Vimentin (i.e. Figure 32, CELL 2) 
and 10% cells were completely negative for this marker (i.e. Figure 32, CELL 3). 
Importantly, no WBCs were positively stained for Vimentin, showing the specificity of this 
marker in detecting melanoma cells. 
 
Figure 32. Microscopic images indicating the differential Vimentin expression intensities 
observed for A2058 melanoma cells spiked into WBCs. The immunostaining shows vimentin 
expression (AF647 -Cy5- Shown here as purple). DAPI (UV- Shown here as blue) was used as a 
nuclear stain and CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. Scale bar 
denotes 15 µm. 
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RANK 
As observed in Figure 33, spiked A2058 cells did not express RANK over the background 
level. In addition, some WBCs showed positive signal for the marker. This findings are 
supported by the literature describing the expression of RANK in WBCs215, 223. 
 
Figure 33. Microscopic images showing the RANK staining pattern in spiking experiments. The 
immunostaining uses an anti-RANK antibody (AF488 -FITC-Showed here as green). DAPI (UV- 
Shown here as blue) was used as a nuclear stain and CD45 (PE -TRITC- Shown here as red) as a 
leukocyte-specific marker. Scale bar denotes 15 µm. 
ABCB5 
As presented in Figure 34, ABCB5 staining was highly specific for melanoma cells, with 
no WBCs staining positive for this marker (i.e. Figure 34, WBC 1). However, the weak 
staining pattern present in A2058 spiked cells showed that this marker is expressed very 
weakly in melanoma cells. A few cells (10%) were stained only at the margins of the cell 
(i.e. Figure 34, CELL 1) and some cells (30%) were stained in a very speckled pattern, 
which makes it difficult to confidently identify them as ABCB5 positive cells (i.e. Figure 
34, CELL 2). The majority of cells were negative for ABCB5 expression. 
 
71 5. RESULTS 
 
Figure 34. Microscopic images showing the ABCB5 staining pattern in spiked cells. The 
immunostaining uses an anti-ABCB5 antibody (R488 -FITC- Shown here as green). DAPI (UV- 
Shown here as blue) was used as a nuclear stain and CD45 (PE -TRITC- Shown here as red) as a 
leukocyte-specific marker. Scale bar denotes 15 µm. 
5.3.4 Tyramide Signal Amplification in ABCB5 marker. 
Tyramide Signal Amplification (TSA) is an enzyme-mediated detection method that 
utilises the catalytic activity of horseradish peroxidase (HRP) to generate a high-density 
labelled target protein thereby providing an intensified staining signal. 
The above results show that A2058 cells express ABCB5 very weakly, complicating the 
detection and characterisation of these ABCB5 positive cells. Therefore, the TSA was 
trialled in order to discover if this method of immunostaining improves the signal shown 
by ABCB5 positive cells, therefore improving their detection. 
Firstly, in order to test the ability of this method to increase and amplify the expression 
signal, MCSP, a marker known for being expressed by A20584, was tested as a positive 
control. When MCSP was tested using the TSA methodology and the same exposure and 
fluorescent intensities for both, standard and TSA immunocytochemistry methods, the 
level of signal observed for MCSP expression was higher (Figure 35.A2) than that of the 
signal obtained by staining with the standard immunocytochemistry protocol (Figure 
35.A1). 
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Next, the ABCB5 expression was tested in order to verify the ability of this method to 
increase the signal produced by A2058 cells that express this marker in low amounts. For 
this, we utilised an antibody that recognises an epitope in a domain of ABCB5 that is 
situated on the external side of the cell membrane (Clone 1D12)217. Results show that, 
compared with the standard immunocytochemistry (ICC) protocol (Figure 35.B1), the 
TSA improved the level of intensity of the signal denoting ABCB5 expression (Figure 
35.B2), allowing the detection of a higher number of ABCB5 positive cells (60%). 
 
Figure 35. Differential signal shown by A2058 cells when comparing the TSA method with 
standard immunocytochemistry. Marker expression of A2058 cells stained with (A1) anti-MCSP 
antibodies (anti-mouse-AF488. Shown here as green), (A2) anti-MCSP antibodies (anti-mouse-
HRP, fluorescein. Shown here as green), and (A3) negative control without primary antibody, 
treated with anti-mouse-HRP (fluorescein). (B1) Cells stained with anti-ABCB5 antibodies (anti-
mouse-AF488. Shown here as green), (B2) anti-ABCB5 antibodies (anti-mouse-HRP, fluorescein. 
Shown here as green), and (B3) negative control without primary antibody, treated with anti-
mouse-HRP (fluorescein). DAPI was used as a nuclear stain (UV- Shown here as blue). Scale bar 
denotes 100 µm. 
Before applying this methodology in samples containing spiked A2058 cells and WBCs, 
the endogenous peroxidase activity of the WBCs was tested. For this, WBCs only were 
stained with isotype antibodies, anti-mouse secondary antibody labelled with HRP and 
then with the TSA Working Solution that contains fluorescein. CD45 antibody was used 
for leukocyte staining. 
In this setting, the fluorescein present in the working solution is normally activated by 
the peroxidase activity of the HRP added to the experimental sample. However, in this 
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case, the presence of peroxidase activity in the WBCs activated the fluorescein, showing 
nonspecific signal in the WBCs (Figure 36.A). This nonspecific fluorescence present in 
WBCs is thought to be due to endogenous peroxidase activity present in the 
eosinophils224. 
In order to block this non-specific background signal and avoid the nonspecific staining, 
three different concentrations of a blocking agent, hydrogen peroxide (H2O2) were tested. 
Results show that by incubating the cells prior to staining with 0.3% H2O2 in PBS for 20 
min, the endogenous peroxidase activity was blocked (Figure 36.B) as the fluorescein 
signal was not detected. 
 
Figure 36. Differential expression pattern in WBCs treated or not with hydrogen peroxide. (A) 
WBCs stained with a mouse isotype control (negative control) and anti-mouse-HRP showing the 
endogenous peroxidase activity (-FITC-Shown here as green). (B) Nonspecific signal quenching 
after treating the sample with 0.3% H2O2. DAPI (UV- Shown here as blue) was used for nuclear 
staining and CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. Scale bar 
denotes 100 µm. 
To study the specificity of this methodology for staining melanoma cells, A2058 cells 
spiked into WBCs were treated with 0.3% H2O2 peroxidase quenching solution and then 
tested for ABCB5 expression. Again, MCSP was used as a positive control, and an isotype 
negative control was also used to detect the background level of non-specific staining. 
Results showed that the majority of A2058 cells (60%) presented with a higher signal 
intensity than that found in previous spiking experiments without TSA amplification 
(Figure 34). 
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The MCSP staining used as a positive control provided a high signal in all spiked A2058 
cells after TSA amplification (Figure 37.B). By contrast, ABCB5 expression was mainly 
present on the periphery of the cells (Figure 37.A), with some cells showing low or no 
staining. This is as expected since ABCB5, a stem cell marker225, is not expected to be 
present in all cells and confirms the specificity of the observed staining. Negative controls 
performed with an isotype antibody were used to define the background level of non-
specific staining (Figure 37.C). 
 
Figure 37. Marker expression of A2058 cells spiked in WBCs. Cells stained with (A) anti-ABCB5 
antibodies at 20 µg/mL (anti-mouse-HRP, fluorescein -FITC- Shown here as green), (B) Positive 
control with anti-MCSP antibodies (anti-mouse-HRP, fluorescein; green), and (C) negative control 
with mouse isotype antibodies DAPI (UV- Shown here as blue) was used as a nuclear stain and 
CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. Scale bar denotes 50 µm. 
In summary, TSA specifically enhanced immunostaining of these two melanoma markers. 
Most importantly, the staining signal of the weakly expressed stem cell marker, ABCB5, 
was significantly improved by TSA, allowing a more accurate detection of the expression 
of this marker in melanoma cells when immunostaining is used for their detection. 
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6. DISCUSSION 
The isolation of CTCs is critical for the understanding of the role of these cells in the 
metastatic process and in determining their utility as biomarkers in the clinical 
management of cancer. The extreme heterogeneity of melanoma CTCs, also demands the 
implementation of better methods for the isolation and identification of the whole 
diversity of melanoma CTCs present in the blood of melanoma patients. Therefore, the 
application of methods that enable the isolation of viable CTCs and detection methods 
that allow the identification of these highly heterogeneous cells, is of high biological and 
clinical significance. 
This project was aimed at developing an optimal procedure for the isolation and 
identification of CTCs in the blood of melanoma patients. The 2X Slanted microfluidic 
device was shown here, for the first time, to allow enrichment of CTCs from the blood of 
metastatic melanoma patients. This is of importance since only two microfluidic devices 
(CTC-iChip and Cluster-Chip) have been utilised previously for the isolation of CTCs from 
melanoma patients178, 185. The protocols required to successfully transfer the microfluidic 
enriched CTCs onto coverslips using the cytospin, and to detect the CTCs by 
immunofluorescence, were also developed. Here the detection of CTCs was achieved 
using a multimarker panel that combines four cellular markers involved in melanocytic 
function and melanomagenesis, commonly used in melanoma diagnosis. Since melanoma 
is a very heterogeneous cancer and melanoma CTCs have been shown to express different 
markers, the expression of three additional markers that can potentially improve the 
possibility of capturing heterogeneous CTCs, was evaluated in melanoma cell lines. 
6.1 Microfluidic devices in melanoma CTC enrichment 
Several methods have been developed to isolate melanoma CTCs from blood samples, 
predominantly using cell surface markers to capture and isolate the CTCs. However, due 
to the extraordinary marker heterogeneity found in melanoma, these methods bias the 
isolation to include only a proportion of CTCs. Thus, methods such as those based on the 
use of microfluidic devices, which isolate CTCs based on their physical properties relative 
to the other blood components, rather than surface marker expression, would improve 
CTC isolation and are thus of significant benefit in melanoma CTC research. 
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Recovery rates 
The study and comparison of the recovery rates and the purity obtained by using 
different spiral microfluidic approaches, determined that the best recovery rate was 
offered by the 1X Slanted chip, which retrieves more than 80% of spiked melanoma cells. 
A similar result has been reported previously by Warkiani et al. for spiked breast and 
bladder cancer cell lines, where a recovery rate of ~85% was achieved11. By contrast, the 
A5 device, failed to capture more than half of the spiked melanoma cells, in contrast to 
previous reported results of >85% of recovery of breast cancer cells (MCF-7)12. 
Surprisingly, the SKMEL5 cells, previously characterised as larger than A2058 cells226, 
showed a lower recovery rate when spiked and processed through the different spiral 
devices. This difference was amplified by the use of the A5 device that recovered, in the 
enriched fraction, only 10.6% of the 50 spiked SKMEL5 compared with 55.3% recovery 
observed when A2058 cells were spiked. It is possible that the A2058 and SKMEL5 cells 
may not only differ in size but also in other physical properties such as cell density or 
deformability, affecting their differential recoveries. Remarkably, previous experiments 
using the multiplexed version of the A5 chip199, also showed a lower recovery rate 
(76.4%) when larger cell line (T24; ~30 µm) rather than a smaller cell line (MCF-7; ~20 
µm) was used (87.6%). 
Additionally, the recovery rates of melanoma cell lines using the A5 microfluidic device 
have not been reported previously. A2058 and SKMEL5 melanoma cell lines have a 
smaller average cell size (13.7 µm and 18.2 µm, respectively226) than the breast cancer 
cells used in A5 studies12. Taken together, the results support the idea that tumour cells 
from the same cancer type may have differential characteristics that may affect their 
recovery rates by microfluidics. Therefore, the use of multiple cancer cell lines is 
recommended when testing the recovery rates of microfluidic enrichment devices for 
CTC isolation. 
Purity 
Although melanoma CTCs have been detected and quantified previously by using label-
dependent methodologies4, 165, 168, 169, one of the most important advantages of using 
label-free isolation methods is the ability to enrich a viable and intact CTC population. 
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This method of isolation allows CTC downstream analyses of CTCs aimed at unveiling the 
genomic and transcriptomic profile of CTCs. Towards this end, achieving a highly purified 
enriched fraction is of vital importance for any type of downstream genomic analysis. 
Given that the purity of the recovered fraction is a high priority for future applications, 
interrogation of the WBC background resulting from these different approaches was 
important and here it is shown for the first time that the enrichment through the A5 chip 
resulted in the highest WBC background when melanoma cells are isolated. Therefore, no 
further experiments were conducted using this spiral device. Although the 1X Slanted 
resulted in a more than 2 log fold reduction of WBC background from the blood of healthy 
donors and patients, this chip showed a higher leukocytic background than previously 
reported of 5 x 103 WBCs per 8 mL11. For this reason, the ability of the 2X Slanted to 
further deplete the WBC background while still providing significant recovery rates, was 
interrogated. The 2X Slanted spiral microfluidic device achieved close to a 3 log reduction 
of WBCs after a second round of Slanted enrichment without markedly affecting the 
enrichment efficiency (>60%). 
However, despite the need to further improve the leukocytic background yielded by the 
slanted device in controls (18,000 WBCs per 8 mL of blood), these values are better than 
those reported for the only other microfluidic device used for melanoma CTCs, the CTC-
iChip (32,000 WBCs per mL of control blood), which was previously used for isolation of 
melanoma CTCs185. 
Further strategies testing the application of additional WBC depletion methodologies to 
blood prior to enrichment through the 2X Slanted enrichment, such Ficoll density 
centrifugation, or negative leukocyte depletion of the enriched fraction after 2X 
Slanted227, are strongly recommended. However, the potential of the Ficoll density 
centrifugation to deplete WBCs prior to microfluidic enrichment needs to be tested since 
these methods could affect physical properties of the cells and therefore affect the 
recovery rates. Another technique that can be used to obtain pure CTCs for downstream 
applications such as single cell sequencing are laser capture microdissection of the cells 
on the stained slide or picking of the cells after the staining. Although these processes 
may increase the purity of the enriched cells, is important to consider that the addition of 
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extra manipulation steps to the enrichment process, may increase cell damage and cell 
loss. 
Ultimately, the combination of the purity and recovery rate of the 2X Slanted offered the 
best outcome amongst the three different spiral microfluidic approaches tested. 
Therefore, this approach was validated for the enrichment of CTCs from the blood of 
metastatic melanoma patients. 
6.2 Detecting CTCs in metastatic melanoma patients  
Detection and quantification of CTCs after enrichment through label-free approaches, 
such as microfluidic devices, is critical for the validation of these isolation techniques. 
In this project, four melanocytic markers (gp100, Melan-A, s100 and MCSP), have been 
used to detect CTCs at a single cell level in the background of thousands of WBCs after 
microfluidic enrichment of patients’ samples226. These markers have been reported to be 
over-expressed in melanoma tumours210, a fact that has driven the extensive use of these 
markers in the capture and detection of CTCs from melanoma patients165, 174, 203, 218, 228. 
Previous studies have detected melanoma CTCs in 40%168, 57%174, 52%170, 79%165, using 
CellSearch®, ISET platform, multimarker flow cytometry and the herringbone CTC-Chip, 
respectively. By using the 2X Slanted microfluidic enrichment method and a multimarker 
panel for immunostaining detection, CTCs were detected in 40% of the metastatic 
melanoma patients analysed. This finding validated, for the first time, the use of the 2X 
Slanted microfluidic device in enriching CTCs from the blood of metastatic melanoma 
patients. However, it is likely that differences in the CTC detection rates across all CTC 
studies may be attributed to the extraordinary heterogeneity of melanoma CTCs both 
within and between patients. Therefore, the ability of label-free methodologies, such as 
the proposed microfluidic approach, to capture a wider population of viable and intact 
CTCs may be beneficial for studies aiming at studying and characterising CTCs using 
phenotypic and single-cell genomic approaches, providing a significant advantage over 
label-dependant methods which do not allow downstream characterisation of detected 
CTCs. 
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Although MCSP is highly expressed in both primary and metastatic lesions229, and 
different methods have detected MCSP positive CTCs4, 98, the immunostaining approach 
used in this project did not detect MCSP positive CTCs in metastatic melanoma patients 
enriched using the 2X Slanted device. Ozkumur et al. have indicated a variability of 
melanoma CTCs in cell size after microfluidic isolation185, but it is still unclear whether 
CTC subtypes do in fact vary in cell size and density. In addition, previous reports 
suggested that the population of CTCs expressing melanocytic markers is lower than the 
subpopulation of CTCs expressing cancer stem cell markers170. 
Based on previous studies4, 170, 174, we expect that not all melanoma CTCs express the 
same markers. Therefore, it is possible that the current markers used in downstream 
approaches for CTC detection may constrain our ability to detect the vast majority of 
melanoma CTC subtypes. Thus, studies aimed at the detection and study of the whole 
range of melanoma CTCs to identify the real diversity of these cells are urgently needed 
in order to pinpoint better markers that minimise false negative results. 
Methods utilised to detect CTCs to date, are derived from our limited available knowledge 
of the whole spectrum of the diversity of melanoma CTCs. Studies are needed therefore 
to investigate melanoma CTC phenotypes and their role in melanoma biology and 
prognosis. Gray et al. found that the proportion of CTCs expressing RANK were 
significantly increased after therapy initiation compared with baseline (p=0.0039) in 
patients treated with BRAF inhibitors (n=16)170. Similarly, CTCs expressing PD-L1 were 
found to be specific biomarkers of response to anti-PD1 blockade171. Thus, prognostic 
utility was found not by using total CTCs counts but by studying subpopulations. 
Additionally, the pharmacodynamics responses of the different subpopulations of CTCs 
to therapy require additional studies to more clearly define the differential relationship 
of these subpopulations with response to drugs170. 
Importantly, the study of different marker subpopulations is of crucial importance in 
melanoma in order to improve our understanding of the role of CTC subpopulations in 
melanoma biology. Previous studies comparing melanoma cell subpopulations between 
patient-matched blood and metastatic tumours, revealed that cell populations expressing 
melanoma initiating markers, such as ABCB5 and RANK, are more common amongst CTCs 
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than in the matching tumour, suggesting a preferential selection for certain tumour cell 
subtypes in the blood170. 
In addition, examining CTC subpopulations and their markers will reveal whether specific 
subsets of CTCs are responsible for metastatic initiation and development, thus aiding in 
a better classification of high-risk patients or patients in need for adjuvant therapies. In 
addition, another important clinical question that could be addressed by characterisation 
of CTC subtypes is the identification of differential response or resistance to metastatic 
melanoma treatments, providing important information that will impact drug design and 
personalised treatment regimes. Such studies will dramatically advance the use of CTCs 
in the clinic. Moreover, optimal isolation of melanoma CTCs paves the way for dissection 
of their real heterogeneity and the mechanisms underlying their role in melanoma 
spreading. 
6.3 Additional markers to detect melanoma CTCs 
Even though great advances have been made in melanoma CTC isolation techniques, 
quantification of melanoma CTCs remains challenging given the low numbers of CTCs 
identified even when multimarker assays are used to detect these cells. This exemplified 
by our results and by other studies165. The high heterogeneity present in melanoma CTCs 
and the low rate of detection of these cells, has highlighted the need to increase the 
marker spectrum applied in detecting CTCs. 
The immunocytochemistry staining protocol used in patients, identified CTCs expressing 
melanocytic markers in 40% of metastatic melanoma patients. However, this method 
would miss cells expressing melanoma-initiating markers, which have been shown to be 
expressed in a great proportion of CTCs170, 215. Here we optimised immunostaining of 
potential markers expressed in melanoma CTCs, including stem-like CTCs in order to 
increase CTC detection rates. 
Vimentin 
Vimentin is an intermediate filaments (IFs) found in the cytoplasm of mesenchymal cells, 
maintaining the structure of the cell and the integrity of the tissue230. The presence of 
Vimentin in melanoma has been defined as a melanoma diagnostic marker213. The 
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detection of this marker in primary tumours has been associated with metastatic 
progression, and therefore with worse outcome212, 231, 232. 
This study tested the expression of Vimentin in 3 melanoma cell lines. Interestingly, this 
marker was expressed by all three cell lines at moderately to high levels. Importantly, 
WBCs do not express this marker, as observed in our spiking experiments. Therefore, this 
marker is now ready to be used together with the multimarker panel in detecting 
melanoma CTCs, Given its high expression in the melanoma cell lines used, it has the 
potential to improve the detection of melanoma CTCs.  
It has been reported previously that only a proportion of CTCs present in the bloodstream 
will ultimately initiate development of a metastatic tumour9. Further studies are needed 
to determine whether Vimentin is a marker of aggressive features in CTCs, which can aid 
in stratifying patients that require more aggressive treatment.  
RANK 
Recently, a flow-cytometry multimarker approach was developed, to detect and analyse 
CTCs for the presence of melanoma-associated markers, such as MCSP and MCAM, in 
combination with melanoma stem cell markers, such as RANK (receptor activator of NF-
κβ), ABCB5 and CD271170. The evidence provided by Gray et al. that the vast majority of 
melanoma CTCs express “stem cell" markers RANK and ABCB5, argues for inclusion of 
such markers in CTC detection by immunocytochemistry. 
In melanoma, RANK has been described as a tumour-initiating cell marker215. In addition, 
Gray et al. found significant association between high numbers of CTCs expressing RANK 
and shorter PFS rates in patients treated with MAPK inhibitors. Therefore, the study of 
this marker expression in melanoma CTCs serves as a prognostic marker for patients 
treated with MAPK inhibitors. 
When studying RANK expression across three melanoma cell lines, cells expressing RANK 
were observed at moderate to low levels. However, when A2058 cells spiked into WBCs 
were assessed, no spiked cells were found positive for RANK. One possible explanation 
for this loss of signal in spiked cells, can be the fact that attached cells express RANK on 
their cell surface. In contrast, spiked cells that have been subjected to important changes 
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in their conditions during spiking, may internalise RANK. In fact, differential staining was 
observed between cells grown on coverslips and those spiked into WBCs for all markers 
tested, supporting the hypothesis that cells stained in spikes suffer loss of cell surface 
markers. 
ABCB5 
The expression of ABCB5, a tumour initiating or ‘stem cell’ marker known to be involved 
in tumour resistance to therapy, was tested in melanoma cell lines and in spiked cells. 
ABCB5 identifies a subset of slow-cycling tumour cells with increased potential to initiate 
metastases217, 233. 
The identification of this marker in melanoma CTCs is of great clinical significance, as it 
is present in increased proportion of CTCs in patients resistant to targeted therapies233. 
Thus, the presence of ABCB5 positive CTCs, may serve as a predictor of poor responses 
to the targeted therapy. Using the staining protocol developed here, we now could 
explore this important question in future studies. 
The study of ABCB5 expression in spiked cells, did not allow confident recognition of 
ABCB5 positive cells. The staining of this marker showed low expression signal in all 
three melanoma cell lines even when stained on coverslips. The TSA system is reported 
to increase the detection of poorly expressed proteins by 100-fold234. By applying this 
methodology to the ABCB5 staining, an increased signal was observed compared with 
standard immunocytochemistry. Now, the ability to detect ABCB5 in the microfluidic 
enriched fraction of metastatic melanoma patients needs to be tested. 
In summary, while previous studies have been able to identify CTCs by using flow 
cytometry, there is an increasing need to unveil the genomic, transcriptomic and 
proteomic signature of CTCs. In order to perform such analyses, label-free approaches, 
such as microfluidics devices, are required. In future studies, microfluidic technology will 
dramatically assist with single-cell genomic downstream analyses. Although this 
methodology requires a high level of optimisation, the addition of multiple markers 
including rare CTC markers, can be a beneficial step towards unveiling the real 
heterogeneity of melanoma CTC subpopulations. 
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6.4 Limitations of the study 
Our study of the isolation of melanoma CTCs has several limitations. One such limitation 
is that there is no knowledge of the ability to detect CTCs in patients with low disease 
burden, even those with metastatic disease, especially when only 8 mL of blood are 
analysed. The analysis of larger amounts of blood would increase the chances of detecting 
CTCs, however, this is not feasible in a clinical setting where patients are required to 
provide several blood samples for other clinical measures. Another limitation is that cell 
lines used here for optimisation of protocols are unlikely to have the same characteristics 
as CTCs. Despite melanoma cell lines being critically useful in understanding melanoma 
biology, the culture conditions of these cell lines might cause some changes to cell 
morphology, biology, and cell surface markers, in particular, when compared to CTCs 
derived from melanoma tumours. Thus, it is possible that cell line cultures derived from 
melanoma tumours may differ in shape or size from the CTCs present in patients. Changes 
in cell size or shape of melanoma CTCs and melanoma cell line cells may induce a different 
interaction with the Dean forces generated inside the micro-channels of these biochips. 
Consequently, changes in the recovery rates of melanoma cell lines compared to CTCs 
derived from patients are likely. 
An additional limitation is the high marker heterogeneity present in CTC populations. 
Although in this project different markers have been utilised to improve the detection of 
CTCs by immunostaining approaches, cell culture conditions may alter the expression of 
certain markers and cell lines may not express the same markers or the same level of 
markers as those found in CTCs. 
On the other hand, the method of enrichment and detection had several steps that could 
have affected the integrity of the cells, interfering with marker expression or cell 
integrity. Also, the processing timeframe of 24 hours could be too long and cause damage 
to the cells, hampering their isolation. To confirm this, studies that investigate marker 
expression on CTCs at several steps along the pathway and processing samples within 4 
hours of collection need to be performed. 
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6.5 Future directions 
Challenges in the isolation and detection of CTCs, particularly in melanoma, have 
hindered studies aimed at unveiling the molecular mechanisms underlying melanoma 
CTC biology and metastasis. 
Moreover, use of the 2X Slanted microfluidic device to isolate viable and label-free 
melanoma CTCs, will pave the way for studies aimed at dissecting their real heterogeneity 
and subsequently the mechanisms underlying their role in melanoma metastasis. 
Although challenging, studying the marker expression, gene expression and mutational 
landscape of single melanoma CTCs, their relationship with tumour tissue cells and their 
connection with treatment response and resistance will significantly increase the clinical 
value of CTCs as a biomarker and dramatically advance CTC use in the clinic. 
6.6 Conclusion 
This project developed and validated the use of a double round of enrichment using the 
Slanted microfluidic device in capturing CTCs from the blood of metastatic melanoma 
patients. A multimarker assay including four common melanoma markers was used in 
order to detect CTCs present in the enriched fraction. This method of enrichment and 
detection identified CTCs in 40 % of the ten metastatic melanoma patients examined. 
Two additional stem cell markers, Vimentin, and ABCB5, have been identified as potential 
markers that can be used in detecting a higher number of melanoma CTCs after spiral 
microfluidic enrichment. The use of TSA in detecting markers that are not highly 
expressed in CTCs but are of great importance in melanoma management will facilitate 
the detection of a broader spectrum of heterogeneous CTCs. 
Ultimately, the isolation of viable, label-free heterogeneous populations of melanoma 
CTCs using this slanted enrichment device will facilitate future studies aimed at unveiling 
the molecular mechanisms and biology of melanoma CTCs and their role in melanoma 
metastasis and response to therapy. 
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8. APPENDICES 
8.1 Supplementary Tables and Figures 
Table S1. Important genes in melanomagenesis2. 
*Abbreviated forms of the gene are given in parentheses. 
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Figure S1. Major pathways involved in melanoma. Pathways associated with cell proliferation, 
survival, and differentiations are schematically presented. Arrows, activating signals; interrupted 
lines, inhibiting signals. AMPK, AMP-activated protein kinase; Aurk, Aurora kinase; BAD, BCL-2 
antagonist of cell death; CDK4, cyclin-dependent kinase 4; CDKN2A, cyclin-dependent kinase 
inhibitor of kinase 2A; ERK, extracellular-related kinase; HGF, hepatocyte growth factor; MITF, 
microphthalmia-associated transcription factor; MEK, mitogen-activated protein kinase-
extracellular-related kinase; PI3K, phosphatidylinositol 3 kinase; PTEN, phosphatase and tensin 
homolog; RB, retinoblastoma protein; TERT, telomerase reverse transcriptase235. 
 
